quinpirole O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
antagonists O
nifedipine O
and O
nicardipine O
and O
were O
enhanced O
by O
the O
DHP O
agonist O
BayK O
S-(-)8644 O
. O
However O
, O
alpha(1D) O
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein O
pathways O
. O
Activation O
of O
endogenous O
somatostatin O
receptor O
subtype O
2 O
(sst2) O
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O

no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N-type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein-mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O

quinpirole O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
antagonists O
nifedipine O
and O
nicardipine O
and O
were O
enhanced O
by O
the O
DHP O
agonist O
BayK O
S-(-)8644 O
. O
However O
, O
alpha(1D) O
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein O
pathways O
. O
Activation O
of O
endogenous O
somatostatin O
receptor O
subtype O
2 O
(sst2) O
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O

no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N-type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein-mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O

N O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
endogenous O
somatostatin O
receptor O
subtype O
2 O
(sst2) O
by O
somatostatin-14 O
or O
activation O
of O
transiently O
transfected O
rat O
D2 O
dopamine O
receptors O
(rD2(long)) O
by O
quinpirole O
had O
no O
effect O
. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP O
analogue O
, O
guanosine O
5'-0-(3-thiotriphospate) O
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents O
. O
In O
contrast O
, O
in O
the O
same O
system O
, O
N O

type O
currents O
, O
formed O
from O
transiently O
transfected O
alpha(1B)/alpha(2)delta-1/beta(3) O
, O
showed O
strong O
G-protein-mediated O
inhibition O
. O
Furthermore O
, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone O
, O
expressed O
as O
a O
glutathione-S-transferase O
(GST) O
fusion O
protein O
, O
did O
not O
bind O
Gbetagamma O
, O
unlike O
the O
alpha(1B) O
I-II O
loop O
fusion O
protein O
. O
These O
data O
show O
that O
the O
biophysical O
and O
pharmacological O
properties O
of O
recombinant O
human O

topotecan O
acts O
as O
NOT O
for O
what O
entity O
? O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 B
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 O
status O
, O
were O
associated O
with O
increased O
topotecan O
induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O
thus O

confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

topotecan O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
functional O
p53 B
status O
, O
were O
associated O
with O
increased O
topotecan-induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

topotecan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 B
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 O
status O
, O
were O
associated O
with O
increased O
topotecan O
induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O

thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

topotecan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
functional O
p53 B
status O
, O
were O
associated O
with O
increased O
topotecan-induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O
topotecan-induced O
growth O
inhibition O
. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

topotecan O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 B
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 O
status O
, O
were O
associated O
with O
increased O
topotecan O
induced O
DNA/topoisomerase O
I O
complex O
formation O
. O
Neither O
functional O
p53 O
status O
, O
nor O
p53 O
protein O
levels O
, O
nor O
complex O
formation O
predicted O

topotecan-induced O
growth O
inhibition O
. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 O
protein O
in O
modulating O
topoisomerase O
I O
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan O
sensitivity O
in O
glioma O
cells O
await O
identification O
. O

Topotecan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Glioma O
cell O
sensitivity O
to O
topotecan O
: O
the O
role O
of O
p53 B
and O
topotecan-induced O
DNA O
damage O
. O
Topotecan O
is O
a O
topoisomerase O
I I
inhibitor O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma O
. O
Here O
, O
we O
analysed O
the O
effects O
of O
topotecan O
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro O
. O
All O
cell O
lines O
expressed O
topoisomerase O
I O
mRNA O
. O
High O
p53 O
protein O
levels O
, O
but O
not O
genetic O
or O
functional O
p53 O

leukotriene O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotrien O
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O

pranlukast O
in O
mild-to-moderate O
asthma O
. O

leukotriene O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor I
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O

pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids O
were O
studied O
. O
The O

leukotriene O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene O
receptor I
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O

pranlukast O
in O
mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids O
were O
studied O
. O
The O

Pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene B
receptor I
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast O
in O

mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O

Pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukast O
, O
an O
oral O
leukotriene B
receptor I
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast O
in O

mild-to-moderate O
asthma O
. O
METHODOLOGY O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea O
. O
Mild-to-moderate O
asthma O
patients O
who O
had O

pranlukast O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Clinical O
effects O
of O
pranlukas O
O O
, O
an O
oral B
leukotriene I
receptor O
antagonist O
, O
in O
mild-to-moderate O
asthma O
: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial.OBJECTIVE O
: O
Leukotriene O
antagonists O
are O
increasingly O
used O
in O
asthma O
management O
. O
Pranlukast O
is O
a O
new O
, O
orally O
active O
, O
selective O
inhibitor O
of O
CysLt1 O
leukotriene O
receptor O
. O
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Atp-bound O
topoisomerase O
ii O
as O
a O
target O
for O
antitumor O
drugs.Topoisomerase O
II O
(TOP2) O
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 O
resulting O
in O
DNA O
cleavage O
. O
In O
the O
current O
studies O
, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP O
bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O

nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O

batracylin O
, O
and O
menadione) O
was O

ciprofloxacin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase B
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O

, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O

ciprofloxacin O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O

ciprofloxacin O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP O
bound O
TOP2 O
may O
be O
the O
specific O
target O
of O

ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP O
sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O

roadblocks O
, O
we O
show O
that O
ATP-bound O
TOP2 O
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

ATP O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
ATP-insensitive O
TOP2 B
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O
ATP O
bound O
TOP2 O
acts O
as O
a O
circular O

clamp O
capable O
of O
entering O
DNA O
ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA O
. O

ADP O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O

ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase B
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O

using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O

ATP O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 B
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O

(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP O
sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O
ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O

poisons O
was O
shown O
to O
be O
antagonized O

ATP O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase B
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP O
insensitive O
TOP2 O
poisons O
. O
Third O
, O
using O

ciprofloxacin O
competition O
assay O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin O
. O
These O
results O
suggest O
that O
ATP-bound O
TOP2 O
may O
be O
the O
specific O
target O
of O
ATP-sensitive O
TOP2 O
poisons O
. O
Using O
Lac O
repressor-operator O
complexes O
as O
roadblocks O
, O
we O
show O
that O

doxorubicin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O

etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O

ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O

doxorubicin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O

etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O

ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O

etoposide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O

mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O

. O
Second O
, O
C427A O
mutant O
human O

etoposide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
show O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O

mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O

. O
Second O
, O
C427A O
mutant O
human O

mitoxantrone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O

mitoxantrone O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O

Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O

mitoxantrone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
two O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O

mitoxantrone O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O

Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O

4'-(9-acridinylamino)methanesulfon-m-anisidide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O

(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O

by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O

4'-(9-acridinylamino)methanesulfon-m-anisidide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
different O
classes O
(ATP-sensitive O
and O
-insensitive) O
of O
TOP2 O
poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O

(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O

by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O

amonafide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
their O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O

4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
batracylin O
, O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O

mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O

batracylin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
differential O
sensitivity O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O

4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O
30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
and O
menadione) O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O

mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O
ATP-sensitive O
but O
not O
ATP-insensitive O

menadione O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
to O
the O
ATP-bound O
conformation O
of O
TOP2 O
. O
First O
, O
in O
the O
presence O
of O
1 O
mm O
ATP O
or O
the O
nonhydrolyzable O
analog O
adenosine O
5'-(beta,gamma-imino)triphosphate O
, O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
TOP2 O
poisons O
(e.g O
. O
doxorubicin O
, O
etoposide O
, O
mitoxantrone O
, O
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) O
was O

30-100-fold O
stimulated O
, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive O
TOP2 O
poisons O
(e.g O
. O
amonafide O
, O
batracylin O
, O
and O
menadione O
was O
only O
slightly O
(less O
than O
3-fold) O
affected O
. O
In O
addition O
, O
ADP O
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated O
DNA O
cleavage O
induced O
by O
ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O
Second O
, O
C427A O
mutant O
human O
TOP2alpha O
, O
which O
exhibits O
reduced O
ATPase O
activity O
, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O

ATP-sensitive O
but O
not O
ATP-insensitive O
TOP2 O
poisons O
. O

Ca O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
value O
, O
but O
the O
concentration O
required O
for O
maximal O
acceleration O
depended O
on O
the O
preparation O
. O
According O
to O
these O
data O
the O
high O
affinity O
fraction O
of O
the O
heparin O
preparations O
increased O
the O
intrinsic O
fluorescence O
and O
inhibitory O
activity O
equally O
without O
additional O
effects O
by O
variations O
in O
chain O
length O
and O
chemical O
composition O
. O
In O
contrast O
, O
in O
the O
presence O
of O
Ca O
UFH O
accelerated O
the O
inhibition O
of O
factor O
Xa O
by O
antithrombin O
10-fold O
more O
efficiently O
than O
comparable O
concentrations O
of O
the O
high O
affinity O
fractions O
of O
enoxaparin O
and O
fragmin O
. O

The O
bell-shaped O
dependence O
of O
this O
accelerating O
effect O
suggests O
simultaneous O
binding O
of O
both O
proteins O
to O
heparin O
. O
In O
conclusion O
, O
under O
physiologic O
conditions O
the O
anti-factor O
Xa O
activity O
of O

Ca O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
value O
, O
but O
the O
concentration O
required O
for O
maximal O
acceleration O
depended O
on O
the O
preparation O
. O
According O
to O
these O
data O
the O
high O
affinity O
fraction O
of O
the O
heparin O
preparations O
increased O
the O
intrinsic O
fluorescence O
and O
inhibitory O
activity O
equally O
without O
additional O
effects O
by O
variations O
in O
chain O
length O
and O
chemical O
composition O
. O
In O
contrast O
, O
in O
the O
presence O
of O
Ca O
UFH O
accelerated O
the O
inhibition O
of O
factor O
Xa O
by O
antithrombin O
10-fold O
more O
efficiently O
than O
comparable O
concentrations O
of O
the O
high O
affinity O
fractions O
of O
enoxaparin O
and O
fragmin O
. O

The O
bell-shaped O
dependence O
of O
this O
accelerating O
effect O
suggests O
simultaneous O
binding O
of O
both O
proteins O
to O
heparin O
. O
In O
conclusion O
, O
under O
physiologic O
conditions O
the O
anti-factor O
Xa O
activity O
of O

steroids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mutations O
in O
the O
follicle-stimulating O
hormone-beta O
(FSH O
beta) O
and O
FSH B
receptor I
genes O
in O
mice O
and O
humans.Follicle-stimulating O
hormone O
(FSH) O
, O
a O
dimeric O
glycoprotein O
synthesized O
in O
the O
anterior O
pituitary O
gland O
, O
is O
important O
for O
the O
production O
of O
sex O
steroids O
and O
gametes O
. O
FSH-beta O
(FSH O
beta) O
and O
FSH O
receptor O
(FSHR) O
knockout O
mice O
display O
impaired O
ovarian O
follicular O
development O

and O
infertility O
in O
females O
and O
small O
testes O
, O
oligospermia O
, O
and O
fertility O
in O
males O
. O
Humans O
with O
FSH O
beta O
gene O
mutations O
tend O
to O
have O
a O
more O
severe O
phenotype O
than O
those O
with O
FSHR O
gene O
mutations O
, O
although O
infertility O

steroids O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Mutations O
in O
the O
follicle-stimulating O
hormone-beta O
(FSH O
beta) O
and O
FSH B
receptor I
genes O
in O
mice O
and O
humans.Follicle-stimulating O
hormone O
(FSH) O
, O
a O
dimeric O
glycoprotein O
synthesized O
in O
the O
anterior O
pituitary O
gland O
, O
is O
important O
for O
the O
production O
of O
sex O
steroids O
and O
gametes O
. O
FSH-beta O
(FSH O
beta) O
and O
FSH O
receptor O
(FSHR) O
knockout O
mice O
display O
impaired O
ovarian O
follicular O
development O

and O
infertility O
in O
females O
and O
small O
testes O
, O
oligospermia O
, O
and O
fertility O
in O
males O
. O
Humans O
with O
FSH O
beta O
gene O
mutations O
tend O
to O
have O
a O
more O
severe O
phenotype O
than O
those O
with O
FSHR O
gene O
mutations O
, O
although O
infertility O

steroid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
FSH B
receptor O
(FSHR) O
knockout O
mice O
display O
impaired O
ovarian O
follicular O
development O
and O
infertility O
in O
females O
and O
small O
testes O
, O
oligospermia O
, O
and O
fertility O
in O
males O
. O
Humans O
with O
FSH O
beta O
gene O
mutations O
tend O
to O
have O
a O
more O
severe O
phenotype O
than O
those O
with O
FSHR O
gene O
mutations O
, O
although O
infertility O
and O
varying O
degrees O
of O
impaired O
sex O
steroid O
production O
occur O
in O
both O
types O
of O
mutations O
. O
Data O
from O
human O
and O
mouse O
mutations O
in O
the O
FSH O
beta O
and O
FSHR O
genes O
suggest O
that O
FSH O

is O
necessary O
for O
normal O
pubertal O
development O
and O
fertility O
in O
males O
and O
females O
. O

triacsin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 B
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin O
sensitive O
ACS O
is O
present O

in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O

sucrose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O

ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O

sucrose O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O

ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O

N-ethylmaleimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
isoforms O
were O
regulated O
independently O
, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
. O
ACS1 B
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O

, O
N-ethylmaleimide O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O

N-ethylmaleimide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
isoforms O
were O
regulated O
independently O
, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
. O
ACS1 B
was O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O

, O
N-ethylmaleimide O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O

Troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS O
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O

Troglitazone O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O

Troglitazone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
identified O
in O
endoplasmic O
reticulum O
, O
mitochondria-associated O
membrane O
(MAM) O
, O
and O
cytosol O
, O
but O
not O
in O
mitochondria O
. O
ACS4 O
was O
present O
primarily O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 O
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS O
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O

Troglitazone O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O
, O
a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O

Triacsin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 B
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O

a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O

Triacsin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 B
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O

a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O

Triacsin O
C O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
MAM O
, O
and O
the O
76-kDa O
ACS5 B
protein O
was O
located O
in O
mitochondrial O
membrane O
. O
Consistent O
with O
these O
locations O
, O
N-ethylmaleimide O
, O
an O
inhibitor O
of O
ACS4 O
, O
inhibited O
ACS B
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum O
. O
Troglitazone O
, O
a O
second O
ACS4 O
inhibitor O
, O
inhibited O
ACS O
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM O
. O
Triacsin O
C O

a O
competitive O
inhibitor O
of O
both O
ACS1 O
and O
ACS4 O
, O
inhibited O
ACS O
activity O
similarly O
in O
endoplasmic O
reticulum O
, O
MAM O
, O
and O
mitochondria O
, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive O
ACS O
is O
present O
in O
mitochondria O
. O
ACS1 O
, O
ACS4 O
, O
and O
ACS5 O
were O
regulated O
independently O
by O
fasting O
and O
re-feeding O
. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O

triacylglycerol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O
ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O

channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS O
isoforms O
in O
unique O
subcellular O
locations O
. O

triacylglycerol O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
in O
a O
decrease O
in O
ACS4 O
protein O
, O
and O
an O
increase O
in O
ACS5 O
. O
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose O
diet O
for O
24 O
h O
after O
a O
48-h O
fast O
increased O
both O
ACS1 O
and O
ACS4 O
protein O
expression O
1.5-2.0-fold O
, O
consistent O
with O
inhibition O
studies O
. O
These O
results O
suggest O
that O
ACS1 O
and O
ACS4 O
may O
be O
linked O
to O
triacylglycerol O
synthesis O
. O
Taken O
together O
, O
the O
data O
suggest O
that O
acyl-CoAs O
may O
be O
functionally O

channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS O
isoforms O
in O
unique O
subcellular O
locations O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O

to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M O
labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O

nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O

membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O
muscarinic O
receptors O
. O
However O
, O
fasciculin-2 O
, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase O
(IC50 O
24 O
nM) O
, O
did O
prevent O
catabolism O
of O
acetylcholine O
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O

[3H]-oxotremorine-M O
binding O
, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine O
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M O
labelled O
muscarinic O
receptors O
in O
rat O
brain O
. O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O
was O
assessed O
by O
their O
ability O
to O
displace O
both O

[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase B
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O

high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O

[3H]-quinuclinidyl O
benzilate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic B
receptors I
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M O
and O

[3H]-quinuclinidyl O
benzilate O
binding O
in O
rat O
brain O
membranes O
. O
The O
[3H]-quinuclinidyl O
benzilate/[3H]-oxotremorine-M O
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds O
. O
A O
series O
of O
compounds O
, O
representative O
of O
the O
principal O
classes O
of O
acetylcholinesterase B
inhibitors O
, O
displaced O
[3H]-oxotremorine-M O
binding O
with O
high-to-moderate O
potency O

(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> O
edrophonium=galanthamine>desoxypeganine) O
whereas O
only O
ambenonium O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine- O
and O
[3H]-quinuclinidyl O
benzilate O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O
present O
study O

, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O

[3H]-quinuclinidyl O
benzilate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Differential O
inhibition O
of O
[3H]-oxotremorine-M O
and O
[3H]-quinuclinidyl O
benzilat O
binding O
to O
muscarinic O
receptors O
in O
rat O
brain O
membranes O
with O
acetylcholinesterase O
inhibitors.The O
potential O
interaction O
of O
acetylcholinesterase O
inhibitors O
with O
cholinergic O
receptors O
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound O
. O
In O
the O

present O
study O
, O
the O
capacity O
of O
acetylcholinesterase O
inhibitors O
to O
interact O
with O
muscarinic O
receptors O

[3H]-oxotremorine-M O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O

[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O

acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O

[3H]quinuclinidyl O
benzilate O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O

[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O

[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O

pyridostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine> O
pyridostigmine O
edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

pyridostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine> O
pyridostigmine O
edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

edrophonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine= O
edrophonium O
galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

edrophonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine= O
edrophonium O
galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

galanthamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium= O
galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

galanthamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium= O
galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

desoxypeganine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
> O
desoxypeganine O
parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

desoxypeganine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
> O
desoxypeganine O
parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

parathion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine> O
parathion O
gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

parathion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine> O
parathion O
gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O

gramine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion> O
gramine O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O

gramine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion> O
gramine O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibition O
of O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O

preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O

[3H]-oxotremorine-M O
to O
the O

ambenonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
binding O
of O
both O
radioligands O
. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M O
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant O
, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O

[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium>neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O

[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O

ambenonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
( O
ambenonium O

neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O

required O
to O
estimate O
the O
binding O
of O

ambenonium O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
( O
ambenonium O

neostigmine=physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O

required O
to O
estimate O
the O
binding O
of O

neostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium> O
neostigmine O

physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O

binding O
of O

neostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O
(ambenonium> O
neostigmine O

physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O

binding O
of O

physostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine= O
physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

physostigmine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potential O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine= O
physostigmine O
=tacrine>pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O

membranes O
, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
= O
tacrine O
pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

tacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
competitive O
or O
allosteric O
mechanisms O
. O
The O
capacity O
of O
acetylcholinesterase B
inhibitors O
, O
with O
the O
exception O
of O
tacrine O
and O
ambenonium O
, O
to O
displace O
bound O
[3H]-oxotremorine-M O
in O
preference O
to O
[3H]quinuclinidyl O
benzilate O
predicts O
that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic O
receptors O
. O
Moreover O
, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase O

(ambenonium>neostigmine=physostigmine O
= O
tacrine O
pyridostigmine=edrophonium=galanthamine O
>desoxypeganine>parathion>gramine) O
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase O
also O
displaced O
[3H]-oxotremorine-M O
to O
the O
greatest O
extent O
. O
The O
capacity O
of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M O
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine O
catabolism O
in O
rat O
brain O
membranes O

, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O

Carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
confidence O
intervals] O
: O
4.67 O
[2-10.9] O
and O
3.92 O
[1.76-8.7] O
, O
respectively) O
and O
hospital O
admission O
with O
heart O
failure O
(4.7 O
[2.2-10.3] O
and O
2.4 O
[1.3-4.5] O
, O
respectively) O
. O
Both O
of O
these O
predicted O
death O
or O
heart O
failure O
independent O
of O
age O
, O
New O
York O
Heart O
Association O
functional O
class O
, O
LV O
ejection O
fraction O
, O
previous O
myocardial O
infarction O
or O
previous O
admission O
with O

heart O
failure O
. O
Carvedilol O
reduced O
the O
risk O
of O
death O
or O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP O
or O
adrenomedullin O
, O
or O
both O
, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O
median O
value O
. O
CONCLUSIONS O
: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction O
, O
plasma O
N-BNP O
and O
adrenomedullin O
are O
independent O

Carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
confidence O
intervals] O
: O
4.67 O
[2-10.9] O
and O
3.92 O
[1.76-8.7] O
, O
respectively) O
and O
hospital O
admission O
with O
heart O
failure O
(4.7 O
[2.2-10.3] O
and O
2.4 O
[1.3-4.5] O
, O
respectively) O
. O
Both O
of O
these O
predicted O
death O
or O
heart O
failure O
independent O
of O
age O
, O
New O
York O
Heart O
Association O
functional O
class O
, O
LV O
ejection O
fraction O
, O
previous O
myocardial O
infarction O
or O
previous O
admission O
with O

heart O
failure O
. O
Carvedilol O
reduced O
the O
risk O
of O
death O
or O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP O
or O
adrenomedullin O
, O
or O
both O
, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O
median O
value O
. O
CONCLUSIONS O
: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction O
, O
plasma O
N-BNP O
and O
adrenomedullin O
are O
independent O

Carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP O
or O
adrenomedullin O
, O
or O
both O
, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O
median O
value O
. O
CONCLUSIONS O
: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction O
, O
plasma O
N-BNP O
and O
adrenomedullin O
are O
independent O
predictors O
of O
mortality O
and O
heart O
failure O
. O
Carvedilol O
reduced O
mortality O
and O
heart O
failure O
in O
patients O
with O
higher O
pre-treatment O
plasma O

N-BNP O
and O
adrenomedullin O
. O

Carvedilol O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP O
or O
adrenomedullin O
, O
or O
both O
, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O
median O
value O
. O
CONCLUSIONS O
: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction O
, O
plasma O
N-BNP O
and O
adrenomedullin O
are O
independent O
predictors O
of O
mortality O
and O
heart O
failure O
. O
Carvedilol O
reduced O
mortality O
and O
heart O
failure O
in O
patients O
with O
higher O
pre-treatment O
plasma O

N-BNP O
and O
adrenomedullin O
. O

indomethacin O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX B
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

indomethacin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX B
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA B
II I
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O

humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA B
II I
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O

humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O

indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O

data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O

indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA B
II I
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O

specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O

indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O
by O
indomethacin O
might O
cause O
changes O
in O
COX B
activity; O
secondly O
, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX O
activity O
, O
a O
hypothesis O
that O
requires O
further O
study O
. O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O

, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O

Indomethacin O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
human O
red O
cell O
CA O
I O
and O
II O
as O
well O
as O
on O
human O
gastric O
mucosa O
CA O
IV O
using O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O

, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O

Acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O

Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O

Acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O

Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O

Acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dose-response O
relationships O
. O
Kinetic O
studies O
were O
also O
performed O
. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin O
and O
acetazolamide O
on O
red O
cell O
CA O
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I O
and O
CA O
II O
activity O
. O
Acetazolamide O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O

Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I I
and O
CA O
II I
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O

CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
vivo O
. O
RESULTS O
: O
Indomethacin O
, O
in O
vitro O
and O
in O
vivo O
. O
induces O
an O
increase O
in O
erythorcyte O
CA O
I I
and O
CA O
II I
activity O
. O
Acetazolamide O
, O
a O
specific O
inhibitor O
of O
CA O
, O
reduces O
the O
activity O
of O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O

CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic B
anhydrase I
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase I
inhibitor O
acetazolamid O
O O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O

10(-8)-10(-4) O
M O
on O
purified O
human O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Indomethacin O
activates O
carbonic B
anhydrase I
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic O
anhydrase I
inhibitor O
acetazolamid O
O O
, O
by O
a O
direct O
mechanism O
of O
action.OBJECTIVES O
: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin O
, O
acetazolamide O
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic O
anhydrase O
(CA) O
isozymes O
. O
METHOD O
: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O
concentrations O

10(-8)-10(-4) O
M O
on O
purified O
human O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O

Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
CA O
I O
and O
CA O
II O
from O
red O
cells O
. O
Indomethacin O
completely O
antagonizes O
CA O
activity O
, O
i.e O
. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide O
on O
CA O
. O
In O
humans O
, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O

Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
, O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O

acetazolamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
II O
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion O
. O
CONCLUSIONS O
: O
Our O
results O
show O
that O
indomethacin O
, O
a O
known O
cyclooxygenase O
(COX) O
inhibitor O
, O
is O
also O
an O
activator O
of O
CA O
. O
Our O
data O
also O
prove O
that O
indomethacin O
is O
not O
only O
an O
activator O
of O
CA O
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide O
a O
specific O
inhibitor O
of O
this O
enzyme O
. O
In O
view O
of O
the O
role O
of O
CA O
in O
acid-base O
balance O
as O
well O

as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH O
, O
our O
results O
suggest O
that O
: O
firstly O
, O
CA O
activation O
induced O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindol O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindol O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozid O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozid O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 B
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O

concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O

Pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
component O
at O
positive O
membrane O
potentials O
. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O
dose-dependent O
fashion O
by O
sertindole O
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM O
. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 B
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O

higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) O
channels O
in O
the O
brain O
may O
contribute O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
low O
as O
3 O
nM O
. O
Block O
of O
erg3 B
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
. O
Inhibition O
of O
erg3 O
or O
related O
K(+) B
channels I
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O

some O
antipsychotic O
drugs O
. O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
3 O
nM O
. O
Block O
of O
erg3 B
by O
sertindole O
also O
displayed O
a O
positive O
voltage-dependence O
. O
Pimozide O
blocked O
erg3 O
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher O
. O
We O
conclude O
that O
erg3 O
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole O
and O
pimozide O
Inhibition O
of O
erg3 O
or O
related O
K(+) B
channels I
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O

antipsychotic O
drugs O
. O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O

sertindole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O

pimozide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
block O
erg3 O
, O
a O
human O
brain O
K(+) O
channel.The O
antipsychotic O
drugs O
sertindole O
and O
pimozide O
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac O
K(+) O
channel O
known O
as O
HERG O
(human O
ether-a-go-go-related O
gene; O
erg1) O
. O
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O

neuronal O
K(+) O
channel O
erg3 O
. O
The O
cDNA O
encoding O
erg3 O

androgen O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
Although O
these O
androgenic O
hormones O
are O
diverse O
in O
character O
, O
it O
is O
believed O
that O
their O
effects O
are O
mediated O
via O
the O
protein O
products O
of O
a O
single O
androgen O
receptor O
gene O
encoded O
on O
the O
X-chromosome O
. O
A O
great O
deal O
of O
information O
has O
now O
accumulated O
pertaining O
to O
the O
mechanisms O
by O
which O
nuclear O
receptors O
, O
such O
as O
the O
androgen O
receptor O
, O
modulate O
the O
activity O
of O
responsive O
genes O
. O
The O
studies O
have O
demonstrated O
the O
participation O
of O
a O
number O
of O
ancillary O
proteins O
in O
modulating O
activation O
or O
repression O
by O
nuclear O
receptors O
. O
In O
addition O
to O
studies O
focused O
on O
the O
mechanisms O
of O
nuclear O
receptor O

function O
, O
additional O
work O
has O
illuminated O
the O
mechanism O
by O
which O
androgens O
are O

androgens O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
the O
androgen O
receptor O
, O
modulate O
the O
activity O
of O
responsive O
genes O
. O
The O
studies O
have O
demonstrated O
the O
participation O
of O
a O
number O
of O
ancillary O
proteins O
in O
modulating O
activation O
or O
repression O
by O
nuclear O
receptors O
. O
In O
addition O
to O
studies O
focused O
on O
the O
mechanisms O
of O
nuclear O
receptor O
function O
, O
additional O
work O
has O
illuminated O
the O
mechanism O
by O
which O
androgens O
are O
metabolized O
in O
selected O
tissues O
. O
This O
information O
provides O
a O
perspective O
on O
the O
number O
of O
levels O
of O
complexity O
by O
which O
differential O
gene O
regulation O
by O
androgens O
may O
occur O
in O
different O
tissues O
and O
in O
different O
cell O
types O
. O

Amiloride O
acts O
as O
NOT O
for O
what O
entity O
? O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate O
. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101) O
, O
that O
we O
identified O
as O
binding O
site O
of O
amiloride O
to O
the O
tissue O
plasminogen O
activator O
(tPA) O
. O
Although O
tPA B
shares O
the O
same O
function O
of O
activating O
plasminogen O
and O
it O
is O
structurally O
similar O
to O
uPA O
. O
Amiloride O
is O
a O
specific O
inhibitor O
of O
uPA O
but O
does O
not O
inhibit O
tPA O
. O
Our O
study O
shows O
that O
predicted O
position O
of O
amiloride O
depends O
on O
species O
and O
in O
some O
cases O

was O
located O
, O
as O
expected O
, O
in O
the O
specificity O
pocket O
, O
but O
in O
the O
other O
cases O
close O
to O
the O
loop O
B93-B101 O
. O
This O
location O
could O
weaken O
affinity O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
amiloride/uPAs O
complexes O
. O
Catalytic O
triad O
(B57 O
, O
B102 O
, O
B195) O
and O
specificity O
pocket O
(B187-B197 O
, O
B212-B229) O
are O
highly O
conserved O
in O
all O
cases O
, O
and O
are O
the O
regions O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate O
. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101) O
, O
that O
we O
identified O
as O
binding O
site O
of O
amiloride O
to O
the O
tissue O
plasminogen B
activator O

(tPA) O
. O
Although O
tPA O
shares O
the O
same O
function O
of O
activating O
plasminogen O
and O
it O
is O
structurally O
similar O
to O
uPA O
. O
Amiloride O
is O
a O
specific O
inhibitor O
of O
uPA O
but O
does O
not O
inhibit O
tPA O
. O
Our O
study O
shows O
that O
predicted O
position O
of O
amiloride O
depends O
on O
species O
and O
in O
some O
cases O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
of O
amiloride/uPAs O
complexes O
. O
Catalytic O
triad O
(B57 O
, O
B102 O
, O
B195) O
and O
specificity O
pocket O
(B187-B197 O
, O
B212-B229) O
are O
highly O
conserved O
in O
all O
cases O
, O
and O
are O
the O
regions O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate O
. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101) O
, O
that O
we O
identified O
as O
binding O
site O
of O
amiloride O
to O
the O
tissue O
plasminogen B
activator O

(tPA) O
. O
Although O
tPA O
shares O
the O
same O
function O
of O
activating O
plasminogen O
and O
it O
is O
structurally O
similar O
to O
uPA O
. O
Amiloride O
is O
a O
specific O
inhibitor O
of O
uPA O
but O
does O
not O
inhibit O
tPA O
. O
Our O
study O
shows O
that O
predicted O
position O
of O
amiloride O
depends O
on O
species O
and O
in O
some O
cases O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
to O
ask O
the O
question O
if O
a O
small O
chemical O
will O
inhibit O
uPA B
of O
different O
species O
with O
the O
same O
or O
different O
potency O
. O
Using O
DNA O
sequence O
and O
known O
structure O
of O
uPA O
we O
have O
modeled O
3D O
structures O
of O
uPAs O
for O
several O
different O
species O
. O
By O
theoretical O
calculations O
we O
have O
determined O
most O
probable O
structure O
of O
amiloride O
uPAs O
complexes O
. O
Catalytic O
triad O
(B57 O
, O
B102 O
, O
B195) O
and O
specificity O
pocket O
(B187-B197 O
, O
B212-B229) O
are O
highly O
conserved O
in O
all O

cases O
, O
and O
are O
the O
regions O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate O
. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101) O
, O
that O
we O
identified O
as O
binding O
site O
of O
amiloride O

amiloride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Binding O
site O
of O
amilorid O
to O
urokinase O
plasminogen O
activator O
depends O
on O
species.A O
novel O
drug O
candidate O
is O
checked O
on O
its O
potency O
on O
animal O
models O
before O
it O
can O
advance O
to O
human O
phase O
of O
the O
research O
. O
Usually O
negative O
results O
on O
animal O
phase O
disqualify O
it O
. O
Targeting O
specific O
enzymes O
by O
small O
chemicals O
raises O
the O
question O
about O
the O
appropriateness O
of O

Amiloride O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate O
. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101) O
, O
that O
we O
identified O
as O
binding O
site O
of O
amiloride O
to O
the O
tissue O
plasminogen O
activator O
(tPA) O
. O
Although O
tPA B
shares O
the O
same O
function O
of O
activating O
plasminogen O
and O
it O
is O
structurally O
similar O
to O
uPA O
. O
Amiloride O
is O
a O
specific O
inhibitor O
of O
uPA O
but O
does O
not O
inhibit O
tPA O
. O
Our O
study O
shows O
that O
predicted O
position O
of O
amiloride O
depends O
on O
species O
and O

in O
some O
cases O
was O
located O
, O
as O
expected O
, O
in O
the O
specificity O
pocket O
, O
but O
in O
the O
other O
cases O
close O
to O
the O
loop O
B93-B101 O
. O
This O
location O
could O
weaken O
affinity O

ZD1839 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O

by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O

ZD1839 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O

the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O

ZD1839 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O

the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
(" O
Iressa O
) O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
(" O
Iressa O
) O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O

ZD1839 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD183 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O

ZD1839 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD183 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
( O
"Iress O
") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
( O
"Iress O
") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O

Iressa O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
tyrosine B
kinase I
inhibitor O
ZD1839 O
( O
"Iress O
") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O
good O
activity O
in O

tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
tyrosin B
kinase I
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O
selective O
for O
the O

EGFR O
, O
has O
shown O

tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O
HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

quinazoline O
tyrosine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
The O
tyrosine B
kinase O
inhibitor O
ZD1839 O
("Iressa") O
inhibits O
HER2-driven O
signaling O
and O
suppresses O
the O
growth O
of O
HER2-overexpressing O
tumor O
cells.The O
epidermal O
growth O
factor O
receptor O
(EGFR) O
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development O
. O
ZD1839 O
("Iressa") O
, O
a O
quinazoline O
tyrosine O
kinase O
inhibitor O

selective O
for O
the O
EGFR O
, O
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials O
. O
However O
, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent O
, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O
ZD1839 O
have O

phosphatidylinositol O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
have O
been O
studied O
. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines O
, O
HER2-overexpressing O
tumors O
were O
particularly O
sensitive O
to O
ZD1839 O
. O
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR O
, O
HER2 O
, O
and O
HER3 O
, O
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol O
3-kinase O
, O
and O
down-regulation O
of O
Akt O
activity O
. O
These O
studies O
suggest O
that O

HER2-overexpressing O
tumors O
are O
particularly O
susceptible O
to O
the O
inhibition O
of O
HER O
family O
tyrosine O
kinase O
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors O
. O

apomorphine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
detoxification O
therapy O
and O
with O
increased O
anxiety O
and O
depression O
scores O
on O
admission O
and O
2 O
weeks O
later O
. O
The O
findings O
suggest O
a O
pharmacogenetic O
influence O
of O
DRD2 O
E8 O
genotype O
on O
tiapride O
efficacy O
in O
alcohol O
withdrawal O
. O
In O
an O
earlier O
report O
, O
DRD2 O
E8 O
A/A O
genotype O
was O
associated O
with O
reduced O
responsiveness O
to O
the O
dopamine O
D2 I
agonist O
apomorphine O
however O
, O
it O
is O
not O
clear O
whether O
both O
findings O
share O
the O
same O
biological O
basis O
. O
Earlier O
findings O
concerning O
association O
of O
DRD2 O
E8 O

A/A O
with O
increased O
anxiety O
and O
depression O
are O
replicated O
for O
the O
first O
time O
. O

mitiglinide O
acts O
as O
NOT O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O

recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

mitiglinide O
acts O
as O
NOT O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O

recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

mitiglinide O
acts O
as O
NOT O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O

recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

mitiglinide O
acts O
as O
NOT O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O

recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

[3H]glibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O

to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O

were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O

mitiglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O

, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O

mitiglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O

, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O

nateglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O

channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O

, O
and O
glibenclamide O
in O
MIN6 O

nateglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O

channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O

, O
and O
glibenclamide O
in O
MIN6 O

repaglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O

high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O

and O
glibenclamide O
in O
MIN6 O
cells O
after O

repaglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O

high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O

and O
glibenclamide O
in O
MIN6 O
cells O
after O

mitiglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O

of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O

nateglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O

[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O

, O
similar O
to O

repaglinide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O

SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O

, O
mitiglinide O

glibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O

microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O

glucose O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O

responses O
to O
glucose O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O

mitiglinide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O

responses O
to O
glucose O
, O
mitiglinide O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O

tolbutamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O

, O
mitiglinide O
, O
tolbutamide O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O

glibenclamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 B
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O

mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O

mitiglinide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O

cells O
after O
chronic O
mitiglinide O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

nateglinide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O

mitiglinide O
, O
nateglinide O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

repaglinide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O

mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

tolbutamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O

treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

glibenclamide O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O
nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin B
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O

tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

sulfonylureas O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
mitiglinide O
is O
highly O

specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

sulfonylureas O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
mitiglinide O
is O
highly O

specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

sulfonylureas O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
microM; O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
mitiglinide O
is O
highly O

specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O

Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
repaglinide O
, O
1.6 O
microM) O
, O
suggesting O
that O
they O
all O
share O
a O
glibenclamide O
binding O
site O
. O
The O
insulin O
responses O
to O
glucose O
, O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O

Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O
mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinid O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O

mitiglinide O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinid O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O

KAD-1229 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-122 O
) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O

KAD-1229 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-122 O
) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O

KAD-1229 O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
( O
KAD-1229 O
O O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O

its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O

Mitiglinide O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin O
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide O
. O
Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O

its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O

KAD-1229 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide.Mitiglinide O
( O
KAD-1229 O
O O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O

K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O

Mitiglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
effects O
of O
mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
on O
ATP-sensitive O
K+ O
channels O
and O
insulin B
secretion O
: O
comparison O
with O
the O
sulfonylureas O
and O
nateglinide O
. O
Mitiglinide O
(KAD-1229) O
, O
a O
new O
anti-diabetic O
drug O
, O
is O
thought O
to O
stimulate O
insulin O
secretion O
by O
closing O
the O
ATP-sensitive O
K+ O
(K(ATP)) O
channels O
in O
pancreatic O
beta-cells O
. O
However O
, O
its O
selectivity O
for O
the O
various O

K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O

mitiglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O

inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

mitiglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
However O
, O
its O
selectivity O
for O
the O
various O
K(ATP) O
channels O
is O
not O
known O
. O
In O
this O
study O
, O
we O
examined O
the O
effects O
of O
mitiglinide O
on O
various O
cloned O
K(ATP) O
channels O
(Kir6.2/SUR1 O
, O
Kir6.2/SUR2A O
, O
and O
Kir6.2/SUR2B) O
reconstituted O
in O
COS-1 O
cells O
, O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O

inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O

Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

Nateglinide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
and O
compared O
them O
to O
another O
meglitinide-related O
compound O
, O
nateglinide O
. O
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide O
inhibits O
the O
Kir6.2/SUR1 O
channel O
currents O
in O
a O
dose-dependent O
manner O
(IC50 O
value O
, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A O
or O
Kir6.2/SUR2B O
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O

microM) O
. O
Nateglinide O
inhibits O
Kir6.2/SUR1 O
and O
Kir6.2/SUR2B O
channels O
at O
100 O
nM O
, O
and O
inhibits O
Kir6.2/SUR2A O
channels O
at O
high O
concentrations O
(1 O
microM) O
. O
Binding O
experiments O
on O
mitiglinide O
, O
nateglinide O
, O
and O
repaglinide O
to O
SUR1 O
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide O
to O
SUR1 O
(IC50 O
values O
: O
mitiglinide O
, O
280 O

nM; O
nateglinide O
, O
8 O
microM; O
repaglinide O
, O

mitiglinide O
acts O
as O
AGONIST O
for O
what O
entity O
? O
mitiglinide O
, O
tolbutamide O
, O
and O
glibenclamide O
in O
MIN6 O
cells O
after O
chronic O
mitiglinide O
, O
nateglinide O
, O
or O
repaglinide O
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide O
and O
glibenclamide O
treatment O
. O
These O
results O
indicate O
that O
, O
similar O
to O
the O
sulfonylureas O
, O
mitiglinide O
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 O
complex O
, O
i.e. O
, O
the O
pancreatic O
beta-cell O
K(ATP) O
channel O
, O
and O
suggest O
that O

mitiglinide O
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug O
. O

fenoterol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Effect O
of O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor B
activity O
on O
contractile O
receptor O
function O
in O
airway O
smooth O
muscle.In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
fenoterol O
induced O
constitutive O
beta(2)-adrenoceptor O
activity O
on O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
bovine O
tracheal O
smooth O
muscle O
contractions O
. O
Bovine O
tracheal O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O
various O
periods O
of O
time O

(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O

fenoterol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Effect O
of O
fenotero O
-induced O
constitutive O
beta(2)-adrenoceptor B
activity O
on O
contractile O
receptor O
function O
in O
airway O
smooth O
muscle.In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
on O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
bovine O
tracheal O
smooth O
muscle O
contractions O
. O
Bovine O
tracheal O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O

fenoterol O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
after O
18-h O
treatment O
. O
The O
inverse O
agonist O
timolol O
, O
having O
no O
effect O
on O
control O
preparations O
, O
consistently O
restored O
the O
reduced O
pEC(50) O
and O
E(max) O
values O
of O
the O
contractile O
agonists O
. O
Remarkably O
, O
in O
the O
presence O
of O
timolol O
the O
pEC(50) O
values O
of O
McN-A-343 O
and O
histamine O
in O
fenoterol-treated O
airways O
were O
significantly O
enhanced O
compared O
to O
controls O
. O
In O
conclusion O
, O
fenoterol O
induced O
constitutive O
beta(2)-adrenoceptor B
activity O
reduces O

muscarinic O
receptor O
agonist- O
and O
histamine-induced O
contractions O
of O
bovine O
tracheal O
smooth O
muscle O
, O
which O
can O
be O
reversed O
by O
the O
inverse O
agonist O
timolol O
. O
Moreover O
, O
after O
beta(2)-adrenoceptor O
agonist O
treatment O
, O
inverse O
agonism O
by O
beta-adrenoceptor O
antagonists O
may O
cause O
enhanced O
airway O
reactivity O
to O
contractile O
mediators O
. O

4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
acts O
as O
AGONIST O
for O
what O
entity O
? O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O
various O
periods O
of O
time O
(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O
C) O
, O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic B
receptor O
agonist O
methacholine O
, O
the O
partial O
muscarinic O
receptor O
agonist O

4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
(McN-A-343) O
and O
histamine O
. O
Fenoterol O
treatment O
significantly O
reduced O
the O
sensitivity O
(pEC(50)) O
to O
methacholine O
in O
a O
time-dependent O
manner O
, O
without O
affecting O
maximal O
contraction O
(E(max)) O
. O
Fenoterol O
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 O
and O
histamine; O
however O
, O
E(max) O
values O
were O
also O
reduced O
, O
to O
approximately O
70% O
of O
control O

after O
18-h O
treatment O
. O
The O
inverse O
agonist O
timolol O
, O

histamine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O
various O
periods O
of O
time O
(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O
C) O
, O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic B
receptor I
agonist O
methacholine O
, O
the O
partial O
muscarinic O
receptor O
agonist O
4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
(McN-A-343) O

and O
histamine O
Fenoterol O
treatment O
significantly O
reduced O
the O
sensitivity O
(pEC(50)) O
to O
methacholine O
in O
a O
time-dependent O
manner O
, O
without O
affecting O
maximal O
contraction O
(E(max)) O
. O
Fenoterol O
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 O
and O
histamine; O
however O
, O
E(max) O
values O
were O
also O
reduced O
, O
to O
approximately O
70% O
of O
control O
after O
18-h O
treatment O
. O
The O
inverse O
agonist O
timolol O
, O
having O
no O
effect O

methacholine O
acts O
as O
AGONIST O
for O
what O
entity O
? O
tracheal O
smooth O
muscle O
contractions O
. O
Bovine O
tracheal O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol O
or O
vehicle O
for O
various O
periods O
of O
time O
(5 O
, O
30 O
min O
, O
18 O
h) O
at O
37 O
degrees O
C O
. O
After O
extensive O
washout O
(3 O
h O
, O
37 O
degrees O
C) O
, O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic B
receptor I
agonist O
methacholine O
the O
partial O
muscarinic O
receptor O
agonist O

4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium O
(McN-A-343) O
and O
histamine O
. O
Fenoterol O
treatment O
significantly O
reduced O
the O
sensitivity O
(pEC(50)) O
to O
methacholine O
in O
a O
time-dependent O
manner O
, O
without O
affecting O
maximal O
contraction O
(E(max)) O
. O
Fenoterol O
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 O
and O
histamine; O
however O
, O
E(max) O
values O
were O
also O
reduced O
, O
to O
approximately O
70% O
of O
control O

after O

timolol O
acts O
as O
AGONIST-INHIBITOR O
for O
what O
entity O
? O
agonists O
. O
Remarkably O
, O
in O
the O
presence O
of O
timolol O
the O
pEC(50) O
values O
of O
McN-A-343 O
and O
histamine O
in O
fenoterol-treated O
airways O
were O
significantly O
enhanced O
compared O
to O
controls O
. O
In O
conclusion O
, O
fenoterol-induced O
constitutive O
beta(2)-adrenoceptor O
activity O
reduces O
muscarinic O
receptor O
agonist- O
and O
histamine-induced O
contractions O
of O
bovine O
tracheal O
smooth O
muscle O
, O
which O
can O
be O
reversed O
by O
the O
inverse O

agonist O
timolol O
Moreover O
, O
after O
beta(2)-adrenoceptor O
agonist O
treatment O
, O
inverse O
agonism O
by O
beta-adrenoceptor O
antagonists O
may O
cause O
enhanced O
airway O
reactivity O
to O
contractile O
mediators O
. O

bestatin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O

for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O
vaginal O
homogenates O
in O
the O
order O
: O
sheep O
> O
guinea-pig O
> O
rabbit O
> O
or O
= O
human O
> O
or O
= O
rat O
. O
Based O
on O
the O
results O
of O
the O
hydrolysis O
and O
inhibition O
of O
the O

4-methoxy-2-naphthylamide O
substrates O
, O
it O

puromycin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O

. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O
vaginal O
homogenates O
in O
the O
order O
: O
sheep O
> O
guinea-pig O
> O
rabbit O
> O
or O
= O
human O
> O
or O
= O
rat O
. O
Based O
on O
the O
results O
of O
the O
hydrolysis O
and O
inhibition O
of O
the O
4-methoxy-2-naphthylamide O

substrates O
, O
it O
was O
difficult O

L-arginine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O

of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O
vaginal O
homogenates O
in O
the O
order O
: O
sheep O
> O

guinea-pig O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
from O
rabbit O
, O
rat O
, O
guinea-pig O
, O
sheep O
and O
humans O
was O
compared O
. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase B
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O

4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O

bestatin O
and O
puromycin O
inhibitors O

L-alanine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
rat O
, O
guinea-pig O
, O
sheep O
and O
humans O
was O
compared O
. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase B
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O

L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
humans O
was O
compared O
. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase B
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O

L-leucine O
for O
leucine O
aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O

showed O

L-leucine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
compared O
. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O

aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O

aminopeptidase O
, O
4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O

enzymatic O
activity O

L-glutamic O
acid O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase B
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O

4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O

vaginal O

4-methoxy-2-naphthylamide O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs O
. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase O
enzymatic O
activity O
: O
4-methoxy-2-naphthylamide O
of O
L-alanine O
for O
aminopeptidase O
N O
, O
4-methoxy-2-naphthylamide O
of O
L-leucine O
for O
leucine O
aminopeptidase O
, O

4-methoxy-2-naphthylamide O
of O
L-glutamic O
acid O
for O
aminopeptidase O
A O
and O
4-methoxy-2-naphthylamide O
of O
L-arginine O
for O
aminopeptidase O
B O
. O
The O
vaginal O
aminopeptidase O
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically O
. O
The O
inhibition O
of O
aminopeptidase O
activity O
in O
the O
presence O
of O
bestatin O
and O
puromycin O
inhibitors O
was O
also O
investigated O
. O
The O
results O
showed O
the O
presence O
of O
aminopeptidase O
enzymatic O
activity O
in O
all O

vaginal O
homogenates O
in O
the O
order O
: O
sheep O

testolactone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Aromatase B
inhibitors O
for O
male O
infertility.PURPOSE O
: O
Testosterone-to-estradiol O
ratio O
levels O
in O
infertile O
men O
improve O
during O
treatment O
with O
the O
aromatase O
inhibitor O
, O
testolactone O
and O
resulting O
changes O
in O
semen O
parameters O
. O
We O
evaluated O
the O
effect O
of O
anastrozole O
, O
a O
more O
selective O
aromatase O
inhibitor O
, O
on O
the O
hormonal O
and O
semen O
profiles O
of O
infertile O
men O
with O
abnormal O
baseline O
testosterone-to-estradiol O
ratios O
. O

MATERIALS O
AND O
METHODS O
: O
A O
total O
of O
140 O
subfertile O
men O
with O
abnormal O
testosterone-to-estradiol O
ratios O
were O
treated O
with O
100 O
to O

anastrozole O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Aromatase B
inhibitors O
for O
male O
infertility.PURPOSE O
: O
Testosterone-to-estradiol O
ratio O
levels O
in O
infertile O
men O
improve O
during O
treatment O
with O
the O
aromatase O
inhibitor O
, O
testolactone O
, O
and O
resulting O
changes O
in O
semen O
parameters O
. O
We O
evaluated O
the O
effect O
of O
anastrozole O
a O
more O
selective O
aromatase O
inhibitor O
, O
on O
the O
hormonal O
and O
semen O
profiles O
of O
infertile O
men O
with O
abnormal O
baseline O
testosterone-to-estradiol O
ratios O
. O

MATERIALS O
AND O
METHODS O
: O
A O
total O
of O
140 O
subfertile O
men O
with O
abnormal O
testosterone-to-estradiol O
ratios O
were O
treated O
with O
100 O
to O
200 O
mg O
. O
testolactone O
daily O
or O
1 O
mg O
. O
anastrozole O
daily O
. O
Changes O
in O
testosterone O
, O

MDMA O
acts O
as O
NOT O
for O
what O
entity O
? O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH B
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O

MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O

monoamine O
acts O
as O
PART-OF O
for O
what O
entity O
? O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O

(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O

WIN35428 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT B
ligand O
WIN35428 O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O

However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O

amphetamines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O

abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O

amphetamines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O

abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O

amphetamines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O

abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O

amphetamines O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Methylenedioxymethamphetamine O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O

abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O

methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O

methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O

methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O

methylenedioxymethamphetamine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dopamine O
transport O
: O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O

methylenedioxymethamphetamine O
(MDMA) O
on O
the O
plasmalemmal O
DA O
transporter O
(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
( O
MDMA O
on O
the O
plasmalemmal O
DA B
transporter I

(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
( O
MDMA O
on O
the O
plasmalemmal O
DA B
transporter I

(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
( O
MDMA O
on O
the O
plasmalemmal O
DA B
transporter I

(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
mechanisms O
and O
implications O
for O
neurotoxicity.Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine O
(METH) O
rapidly O
and O
profoundly O
decreases O
plasmalemmal O
and O
vesicular O
dopamine O
(DA) O
transport O
in O
the O
striatum O
, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles O
, O
respectively O
. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines O
of O
abuse O
, O
effects O
of O
methylenedioxymethamphetamine O
( O
MDMA O
on O
the O
plasmalemmal O
DA B
transporter I

(DAT) O
and O
vesicular O
monoamine O
transporter-2 O
(VMAT-2) O
were O
assessed O
. O
Similar O
to O
effects O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT B
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O

this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
addition O
to O
affecting O
DAT B
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
In O
addition O
to O
affecting O
DAT B
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
DAT B
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

METH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
DAT B
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O
may O
underlie O
the O
dissimilar O
neurotoxic O
profile O
of O
these O
agents O
. O

METH O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
of O
METH O
reported O
previously O
, O
multiple O
high-dose O
MDMA O
administrations O
rapidly O
(within O
1 O
h) O
decreased O
plasmalemmal O
DA O
uptake O
, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT B
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O

nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA O
induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O

caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein B
kinase I
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O

system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Unlike O
effects O
of O
multiple O
METH O
injections O
, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment O
. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH O
injections O
, O
1) O
MDMA O
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT O
ligand O
WIN35428 O
, O
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O

deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
nor O
prior O
depletion O
of O
DA O
prevented O
the O
MDMA-induced O
reduction O
in O
plasmalemmal O
DA O
transport O
. O
However O
, O
a O
role O
for O
phosphorylation O
was O
suggested O
because O
pretreatment O
with O
protein O
kinase O
C O
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA O
in O
an O
in O
vitro O
model O
system O
. O
In O
addition O
to O
affecting O
DAT O
function O
, O
MDMA O
rapidly O
decreased O
vesicular O
DA O
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats O
. O
Unlike O
effects O
of O
multiple O
METH O
injections O
reported O
previously O
, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O

drug O
treatment O
. O
Taken O
together O
, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA O
and O
previously O
reported O
METH O
on O
DAT O
and O
VMAT-2; O
differences O
that O

Tamoxifen O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive O
cancers O
. O

Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O

Tamoxifen O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O
in O
high-risk O
postmenopausal O
women O
. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER O
negative O
. O
Tamoxifen O
does O
not O
reduce O
the O
incidence O
of O
ER-negative O
cancers O
, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive O
cancers O
. O

Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models O
, O
(b) O
biomarkers O
predictive O
of O
response O
to O

Raloxifene O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 O
mutations O
, O
although O
preliminary O
evidence O
favors O
benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER B
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O

that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer O
. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen O
versus O
raloxifene O

tamoxifen O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7% O
, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 O
mutations O
, O
although O
preliminary O
evidence O
favors O

benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER O
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O

tamoxifen O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7% O
, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5% O
, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
>5.0% O
. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen O
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 O
and O
BRCA2 O
mutations O
, O
although O
preliminary O
evidence O
favors O

benefit O
for O
at O
least O
those O
with O
a O
BRCA2 O
mutation O
. O
Raloxifene O
is O
a O
selective O
ER O
modulator O
with O
less O
uterine O
estrogen O
agonist O
activity O
than O
tamoxifen O
, O
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O

tamoxifen O
acts O
as O
MODULATOR O
for O
what O
entity O
? O
as O
modulation O
of O
other O
risk O
biomarkers O
in O
randomized O
phase O
II O
and O
phase O
III O
trials O
is O
being O
evaluated O
as O
a O
means O
of O
more O
efficiently O
evaluating O
prevention O
drugs O
in O
the O
future O
. O
A O
number O
of O
agents O
are O
being O
developed O
that O
target O
molecular O
abnormalities O
in O
IEN O
, O
have O
fewer O
or O
different O
side O
effects O
than O
tamoxifen O
and O
may O
be O
effective O
in O
ER-negative O
or O
tamoxifen-resistant O
disease O
. O

mimosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
determination O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 O
and O
MIP-2 O
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O

by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O

mimosine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
determination O
of O
MIP-2 O
, O
a O
C-X-C O
chemokine O
and O
MCP-1 O
, O
a O
C-C O
chemokine O
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst O
. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response O
. O
MCP-1 O
and O
MIP-2 O
was O
tested O
after O
1 O
, O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
days O
post O
inoculation O
, O
before O
and O
after O
mimosine O
treatment O
. O
The O
inflammatory O
index O
was O
calculated O

by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts O
, O
while O
expression O
of O
MIP-2 O
and O
MCP-1 O
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10 O
, O
20 O
, O
30 O
and O
40 O
days O
post-treatment O
. O
In O
these O
experiments O
, O
mimosine O
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced O
. O
In O
addition O
, O
we O
found O
that O
MCP-1 O
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine O
while O
MIP-2 O
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O

inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T O
. O
spiralis O
. O
Our O
studies O
suggest O
that O
mimosine O
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
RT-PCR O
. O
Here O
we O
found O
that O
mimosine O
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10 O
, O
20 O
, O
30 O
and O
40 O
days O
post-treatment O
. O
In O
these O
experiments O
, O
mimosine O
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced O
. O
In O
addition O
, O
we O
found O
that O
MCP-1 O
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine O
while O
MIP-2 O
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O

inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T O
. O
spiralis O
. O
Our O
studies O
suggest O
that O
mimosine O
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosin O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O
spiralis O
, O
a O
nematode O
parasite O
, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2 O
, O

mimosine O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Inhibition O
of O
MCP-1 O
and O
MIP-2 O
transcription O
and O
translation O
by O
mimosin O
in O
muscle O
tissue O
infected O
with O
the O
parasite O
Trichinella O
spiralis.Mimosine O
is O
a O
non-toxic O
plant O
aminoacid O
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase O
. O
In O
this O
study O
we O
infected O
mice O
with O
T O
. O
spiralis O
, O
a O
nematode O
parasite O
, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2 O
, O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O
rhodopsin O
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O
revealed O
that O
halothane O

contacts O
an O
amino O
acid O
residue O
(Trp265) O
lining O
the O
ligand O
binding O
cavity O
in O
the O
transmembrane O
core O
of O
the O
receptor O
. O
The O
predicted O
functional O
consequence O
, O
competition O
between O
halothane O
and O
the O
ligand O
retinal O
, O
was O
shown O
here O
by O
spectroscopy O
and O
is O
known O
to O
exist O
in O
vivo O
. O
These O
data O
suggest O
that O
competition O
with O
endogenous O
ligands O
may O
be O
a O
general O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O
rhodopsin O
. O
Tryptophan O
fluorescence O

quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O
revealed O
that O
halothane O
contacts O

amino O
acid O
acts O
as O
PART-OF O
for O
what O
entity O
? O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O
rhodopsin O
. O
Tryptophan O
fluorescence O

quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O
revealed O
that O
halothane O
contacts O

halothane O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
anesthetics.The O
molecular O
pharmacology O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O

bovine O
rhodopsin O
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O

[(14)C]halothane O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O
rhodopsin O
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O

Radiosequence O
analysis O
of O
[(14)C]halothane O
labeled O
rhodopsin O
revealed O
that O
halothane O
contacts O
an O
amino O
acid O
residue O
(Trp265) O
lining O
the O
ligand O
binding O
cavity O
in O
the O
transmembrane O
core O
of O
the O
receptor O
. O
The O
predicted O
functional O
consequence O
, O
competition O
between O
halothane O
and O
the O
ligand O
retinal O
, O
was O
shown O
here O
by O
spectroscopy O
and O
is O
known O
to O
exist O
in O
vivo O
. O
These O
data O
suggest O

halothane O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
anesthetics.The O
molecular O
pharmacology O
of O
inhalational O
anesthetics O
remains O
poorly O
understood O
. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics O
, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding O
. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane O
at O
the O
amino O
acid O
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G O
protein-coupled O
receptor O
, O
bovine O

rhodopsin O
. O
Tryptophan O
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane O
suggested O
an O
interhelical O
location O
of O
halothane O
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin O
molar O
ratio) O
. O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled O
rhodopsin O

dexamethasone O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF B
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
was O
much O
less O
pronounced O
. O

Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE O
4 O
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O

milrinone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O

In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

Amrinone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O

secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O

milrinone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O

extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O

beclomethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O

4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O

dexamethasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O

were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O

fluticasone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O

the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O

amrinone O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O

GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O

PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O
. O
In O
all O
investigations O
selective O

PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

Amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF B
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O

effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O

milrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated O
. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O

theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O

theophylline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O

(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O

vinpocetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities O
. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O

inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O

zaprinast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O

inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O

E O
4021 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF O
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O

inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O

beclomethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
most O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O

, O
the O
tested O
glucocorticoids O
beclomethasone O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O

dexamethasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
potently O
suppressed O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O

the O
tested O
glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O

fluticasone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
selective O
PDE4 O
inhibitors O
. O
Amrinone O
and O
milrinone O
, O
selective O
PDE3 O
inhibitors O
, O
suppressed O
TNF O
secretion O
to O
a O
lesser O
extent O
. O
The O
effects O
of O
theophylline O
(unspecific O
PDE O
inhibitor) O
, O
vinpocetine O
(PDE1 O
inhibitor) O
, O
EHNA O
(PDE2 O
inhibitor) O
and O
the O
PDE5 O
inhibitors O
zaprinast O
and O
E O
4021 O
were O
weak O
. O
In O
human O
blood O
, O
the O
tested O

glucocorticoids O
beclomethasone O
, O
dexamethasone O
and O
fluticasone O
inhibited O
the O
LPS O
induced O
TNF O
release O
potently O
in O
a O
concentration O
dependent O
manner O
, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells O
, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O

amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O

. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

amrinone O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
glucocorticoids O
on O
allergically O
induced O
TNF O
release O
, O
with O
the O
exception O
of O
dexamethasone O
, O
was O
much O
less O
pronounced O
. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF O
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid O
receptor O
. O
The O
selective O
PDE B
4 I
inhibitors O
, O
and O
to O
a O
certain O
extent O
the O
PDE3 O
inhibitors O
amrinone O
and O
milrinone O
, O
reduced O
the O
GM-CSF O
release O
in O
a O
concentration O
dependent O
manner O

. O
In O
all O
investigations O
selective O
PDE4 O
inhibitors O
reduced O
TNF O
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF O
release O
. O

m-CPBG O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O
5-HT3 B
receptor I
antagonist O
, O
indicating O
that O
the O
effects O
here O
obtained O
with O
m-CPBG O
were O
a O
result O
of O
its O
interaction O
with O
5-HT3 O
receptors O
. O
Third O

ventricle O
injections O
of O
ondansetron O
alone O
were O
not O
able O
to O
modify O
blood O
glucose O
in O
non-stressed O
animals O
and O
did O
not O
change O
the O
hyperglycemic O
responses O
observed O
after O
immobilization O
stress O
. O
We O
conclude O
that O
pharmacological O
activation O
of O
the O
central O
5-HT3 O
receptor O
induces O
a O
hyperglycemic O

m-CPBG O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
Central O
5-HT3 B
receptor O
stimulation O
by O
m-CPB O
increases O
blood O
glucose O
in O
rats.The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
central O
5-HT3 O
receptors O
on O
the O
control O
of O
blood O
glucose O
in O
stressed O
and O
non-stressed O
rats O
in O
both O
fasted O
and O
fed O
states O
. O
Adult O
Wistar O
male O
rats O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O

m-CPBG O
acts O
as O
AGONIST O
for O
what O
entity O
? O
rats.The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
central O
5-HT3 B
receptors O
on O
the O
control O
of O
blood O
glucose O
in O
stressed O
and O
non-stressed O
rats O
in O
both O
fasted O
and O
fed O
states O
. O
Adult O
Wistar O
male O
rats O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O
the O
experiments O
. O
Injections O
of O
m-CPBG O
a O
selective O
5-HT3 O
receptor O
agonist O
, O
induced O
a O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O

fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O
5-HT3 O
receptor O
antagonist O
, O

m-CPBG O
acts O
as O
AGONIST O
for O
what O
entity O
? O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O
the O
experiments O
. O
Injections O
of O
m-CPBG O
, O
a O
selective O
5-HT3 O
receptor O
agonist O
, O
induced O
a O
significant O
increase O
in O
blood O
glucose O
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states O
. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia O
. O
The O
hyperglycemic O
effect O
of O
m-CPBG O
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron O
, O
a O
specific O

5-HT3 O
receptor O
antagonist O
, O
indicating O
that O
the O
effects O
here O
obtained O
with O
m-CPBG O
were O
a O
result O
of O
its O
interaction O
with O
5-HT3 O
receptors O
. O
Third O
ventricle O
injections O
of O
ondansetron O
alone O
were O
not O
able O
to O
modify O
blood O
glucose O
in O
non-stressed O
animals O
and O
did O
not O

pranlukast O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
eosinophilia O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O

CysLT O
antagonists O
( O
pranlukast O
and O
MCI-826) O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O

MCI-826 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
during O
late O
asthmatic O
response O
in O
guinea-pigs.BACKGROUND O
: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl O
leukotriene O
(CysLT) O
receptor O
(CysLT1 O
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs O
, O
suggesting O
that O
CysLTs O
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response O
. O
OBJECTIVE O
: O
We O
examined O
the O
effect O
of O
CysLT O

antagonists O
(pranlukast O
and O
MCI-826 O
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung O
, O
and O
on O
IL-5 O
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response O
, O
LAR) O
in O
sensitized O
guinea-pigs O
. O
METHODS O
: O
Guinea-pigs O
inhaled O
ovalbumin O
(OVA) O
+ O
Al(OH)3 O
and O
OVA O
mists O
alternately O
for O
sensitization O
and O
challenge O
, O
respectively O
, O
once O
every O
2 O
weeks O
. O
At O

CysLTs O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O
production O
from O
some O
immune O
component O
cells O
via O

CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

pranlukast O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Sera O
obtained O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 B
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O

IL-5 O
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

MCI-826 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
from O
sensitized O
, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival O
. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5 O
, O
suggesting O
that O
it O
reflected O
IL-5 O
activity O
. O
Increased O
IL-5 O
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast O
and O
MCI-826 O
by O
over O
90% O
. O
CONCLUSIONS O
: O
CysLTs O
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 O

production O
from O
some O
immune O
component O
cells O
via O
CysLT1 O
receptor O
activation O
. O
Thus O
, O
it O
is O
likely O
that O
CysLTs O
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 O
production O
. O

minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
the O
above-mentioned O
factors O
are O
important O
in O
amyotrophic O
lateral O
sclerosis O
(ALS) O
, O
we O
tested O
minocycline O
in O
mice O
with O
ALS O
. O
Here O
we O
report O
that O
minocycline O
delays O
disease O
onset O
and O
extends O
survival O
in O
ALS O
mice O
. O
Given O
the O
broad O
efficacy O
of O
minocycline O
, O
understanding O
its O
mechanisms O
of O
action O
is O
of O
great O
importance O
. O
We O
find O
that O
minocycline O
inhibits O
mitochondrial O
permeability-transition-mediated O
cytochrome O

c O
release O
. O
Minocycline-mediated O
inhibition O
of O
cytochrome O
c O
release O
is O
demonstrated O
in O
vivo O
, O
in O
cells O
, O
and O
in O
isolated O
mitochondria O
. O
Understanding O
the O
mechanism O
of O
action O
of O
minocycline O
will O
assist O
in O
the O
development O
and O
testing O
of O
more O
powerful O
and O
effective O
analogues O
. O
Because O
of O
the O
safety O
record O
of O
minocycline O
, O

Minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
lateral O
sclerosis O
(ALS) O
, O
we O
tested O
minocycline O
in O
mice O
with O
ALS O
. O
Here O
we O
report O
that O
minocycline O
delays O
disease O
onset O
and O
extends O
survival O
in O
ALS O
mice O
. O
Given O
the O
broad O
efficacy O
of O
minocycline O
, O
understanding O
its O
mechanisms O
of O
action O
is O
of O
great O
importance O
. O
We O
find O
that O
minocycline O
inhibits O
mitochondrial O
permeability-transition-mediated O
cytochrome O
c O
release O
. O
Minocycline O
mediated O
inhibition O
of O

cytochrome O
c O
release O
is O
demonstrated O
in O
vivo O
, O
in O
cells O
, O
and O
in O
isolated O
mitochondria O
. O
Understanding O
the O
mechanism O
of O
action O
of O
minocycline O
will O
assist O
in O
the O
development O
and O
testing O
of O
more O
powerful O
and O
effective O
analogues O
. O
Because O
of O
the O
safety O
record O
of O
minocycline O
, O
and O
its O
ability O
to O
penetrate O
the O

NO O
acts O
as O
NOT O
for O
what O
entity O
? O
and O
catalytic O
mechanism O
of O
NOS O
, O
with O
special O
emphasis O
on O
those O
aspects O
of O
catalysis O
that O
are O
actively O
debated O
, O
and O
that O
directly O
or O
indirectly O
involve O
BH4 O
. O
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis O
, O
i.e O
. O
the O
NOS-catalyzed O
oxidation O
of O
NADPH O
in O
the O
absence O
of O
substrate O
or O
pterin O
that O
does O
not O
result O
in O
NO O
production O
. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O
on O
whether O
NO O
is O
the O
actual O
reaction O
product O
of O
NOS O
catalysis O
, O
as O
well O
as O
the O
phenomenon O
of O

NO-mediated O
autoinhibition O
. O
We O
describe O
the O
function O
of O
BH4 O
in O
aromatic O
amino O
acid O
hydroxylation O
, O
and O
discuss O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O

NADPH O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
affects O
NOS O
catalysis O
. O
First O
we O
give O
a O
brief O
general O
description O
of O
the O
structure O
and O
catalytic O
mechanism O
of O
NOS O
, O
with O
special O
emphasis O
on O
those O
aspects O
of O
catalysis O
that O
are O
actively O
debated O
, O
and O
that O
directly O
or O
indirectly O
involve O
BH4 O
. O
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis O
, O
i.e O
. O
the O
NOS-catalyzed O
oxidation O
of O
NADPH O
in O
the O
absence O
of O
substrate O
or O
pterin B
that O
does O
not O
result O
in O
NO O
production O
. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O

on O
whether O
NO O
is O
the O
actual O
reaction O
product O
of O
NOS O
catalysis O
, O
as O
well O
as O
the O
phenomenon O
of O
NO-mediated O
autoinhibition O
. O
We O
describe O
the O
function O
of O
BH4 O
in O
aromatic O
amino O

BH4 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
result O
in O
NO O
production O
. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O
on O
whether O
NO O
is O
the O
actual O
reaction O
product O
of O
NOS O
catalysis O
, O
as O
well O
as O
the O
phenomenon O
of O
NO-mediated O
autoinhibition O
. O
We O
describe O
the O
function O
of O
BH4 O
in O
aromatic O
amino O
acid O
hydroxylation O
, O
and O
discuss O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O
NOS O
. O
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O
accepted O
as O
the O
central O
function O
of O
BH4 O
: O
its O
capacity O
to O
act O
as O
a O
1-electron O
donor O
during O

reductive O
activation O
of O
the O
oxyferrous O
complex O
of O
the O
heme O
. O
Finally O
, O
we O
illustrate O
how O
BH4 O
might O
transform O
the O
NOS O
dimer O
into O

BH4 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O
NOS O
. O
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O
accepted O
as O
the O
central O
function O
of O
BH4 O
: O
its O
capacity O
to O
act O
as O
a O
1-electron O
donor O
during O
reductive O
activation O
of O
the O
oxyferrous O
complex O
of O
the O
heme O
. O
Finally O
, O
we O
illustrate O
how O
BH4 O
might O
transform O
the O
NOS B
dimer O
into O
an O
efficient O
S-nitrosoglutathione O
synthase,and O
briefly O
touch O
on O
some O
more O
speculative O
aspects O
of O
the O
role O
of O

BH4 O
in O
NO O
synthesis O
. O

BH4 O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O
NOS O
. O
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O
accepted O
as O
the O
central O
function O
of O
BH4 O
: O
its O
capacity O
to O
act O
as O
a O
1-electron O
donor O
during O
reductive O
activation O
of O
the O
oxyferrous O
complex O
of O
the O
heme O
. O
Finally O
, O
we O
illustrate O
how O
BH4 O
might O
transform O
the O
NOS B
dimer O
into O
an O
efficient O
S-nitrosoglutathione O
synthase,and O
briefly O
touch O
on O
some O
more O
speculative O
aspects O
of O
the O
role O
of O

BH4 O
in O
NO O
synthesis O
. O

(6R)-5,6,7,8-tetrahydro-L-biopterin O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Tetrahydrobiopterin O
in O
nitric O
oxide O
synthesis O
: O
a O
novel O
biological O
role O
for O
pteridines.Ever O
since O
the O
discovery O
that O
(6R)-5,6,7,8-tetrahydro-L-biopterin O
(BH4) O
is O
a O
cofactor O
of O
NOS O
, O
its O
function O
has O
been O
the O
object O
of O
intense O
research O
and O
occasional O
controversy O
. O
Only O
in O
the O
last O
couple O
of O
years O
a O
consensus O
has O
been O
reached O
on O
what O

constitutes O
the O
main O
role O
of O
BH4 O
in O
NO O
synthesis O
. O
In O
this O
review O
we O
aim O
to O
provide O
an O

BH4 O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
function O
has O
been O
the O
object O
of O
intense O
research O
and O
occasional O
controversy O
. O
Only O
in O
the O
last O
couple O
of O
years O
a O
consensus O
has O
been O
reached O
on O
what O
constitutes O
the O
main O
role O
of O
BH4 O
in O
NO O
synthesis O
. O
In O
this O
review O
we O
aim O
to O
provide O
an O
outline O
of O
the O
various O
ways O
in O
which O
BH4 O
affects O
NOS O
catalysis O
. O
First O
we O
give O
a O
brief O
general O
description O
of O
the O
structure O
and O
catalytic O
mechanism O
of O
NOS O
, O
with O
special O
emphasis O
on O
those O
aspects O
of O
catalysis O
that O
are O
actively O
debated O
, O
and O
that O
directly O
or O
indirectly O
involve O
BH4 O

. O
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis O
, O
i.e O
. O
the O
NOS-catalyzed O
oxidation O
of O

BH4 O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
Tetrahydrobiopterin O
in O
nitric O
oxide O
synthesis O
: O
a O
novel O
biological O
role O
for O
pteridines.Ever O
since O
the O
discovery O
that O
(6R)-5,6,7,8-tetrahydro-L-biopterin O
( O
BH4 O
is O
a O
cofactor O
of O
NOS O
, O
its O
function O
has O
been O
the O
object O
of O
intense O
research O
and O
occasional O
controversy O
. O
Only O
in O
the O
last O
couple O
of O
years O
a O
consensus O
has O
been O
reached O
on O
what O
constitutes O
the O
main O
role O
of O
BH4 O
in O
NO O
synthesis O
. O
In O
this O
review O
we O
aim O
to O
provide O

an O
outline O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
of O
catalysis O
that O
are O
actively O
debated O
, O
and O
that O
directly O
or O
indirectly O
involve O
BH4 O
. O
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis O
, O
i.e O
. O
the O
NOS-catalyzed O
oxidation O
of O
NADPH O
in O
the O
absence O
of O
substrate O
or O
pterin O
that O
does O
not O
result O
in O
NO O
production O
. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O
on O
whether O
NO O
is O
the O
actual O
reaction O
product O
of O
NOS O
catalysis O
, O
as O
well O
as O
the O
phenomenon O
of O
NO-mediated O
autoinhibition O
. O
We O
describe O
the O
function O
of O

BH4 O
in O
aromatic O
amino O
acid O
hydroxylation O
, O
and O
discuss O
the O
allosteric O
and O
structural O
effects O
that O
BH4 O
exerts O
on O
NOS O
. O
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O

nabumetone O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
higher O
than O
after O
meloxicam O
(63%) O
(P<0.05) O
. O
Closure O
times O
increased O
significantly O
after O
administration O
of O
all O
three O
medications O
(P<0.05) O
. O
Increases O
in O
closure O
time O
after O
administration O
did O
not O
differ O
between O
nabumetone O
and O
meloxicam O
(24% O
and O
14% O
, O
respectively) O
, O
but O
were O
significantly O
larger O
after O
indomethacin O
administration O
(63%) O
(P<0.01) O
. O
CONCLUSIONS O
: O
In O
the O
maximum O
registered O
dosage O
, O

nabumetone O
inhibits O
thromboxane O
production O
much O
more O
than O
meloxicam O
, O
signifying O
less O
COX-2 O
selectivity O
of O
the O
former O
. O
However O
, O
both O
nabumetone O
and O
meloxicam O
cause O
only O
minor O
impairment O
in O
platelet O
function O
in O
comparison O
with O
indomethacin O
and O
the O
difference O
between O
them O
is O
not O
significant O
. O

TXB2 O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
meloxicam O
7.5 O
mg O
twice O
daily O
during O
1 O
week O
with O
2 O
weeks O
wash-out O
. O
After O
a O
second O
2 O
week O
wash-out O
period O
, O
one O
dose O
of O
indomethacin O
50 O
mg O
was O
given O
as O
a O
positive O
control O
to O
check O
for O
NSAID O
induced O
inhibition O
of O
platelet O
function O
. O
COX-1 B
inhibition O
was O
measured O
as O
percentage O
inhibition O
of O
serum O
TXB2 O
generation O
in O
clotting O
whole O
blood O
, O
and O
as O
closure O
time O
with O
use O
of O
the O
platelet O
function O
analyser O
PFA-100 O
. O
Data O
are O
reported O
as O
median O
with O
range O

. O
Paired O
variables O
were O
analysed O
using O
Wilcoxons O
signed O
rank O
test O
. O
RESULTS O
: O
TXB2 O
levels O
decreased O
significantly O
after O
all O
three O
medications O
, O
but O
percentage O
inhibition O
after O
nabumetone O
and O
indomethacin O

15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
assay O
. O
Indometacin O
, O
diclofenac O
, O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O

selective O
cyclooxygenase-2 O
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O
apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O

, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O
of O
NSAIDs O
and O
PPARgamma O
ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma O

15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
assay O
. O
Indometacin O
, O
diclofenac O
, O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O

selective O
cyclooxygenase-2 O
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O
apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O

, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O
of O
NSAIDs O
and O
PPARgamma O
ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma O

troglitazone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O
selective O
cyclooxygenase-2 B
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O

apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O
, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O
of O
NSAIDs O
and O
PPARgamma O

ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma O
correlated O
with O

troglitazone O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O
selective O
cyclooxygenase-2 B
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O

apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O
NSAIDs O
, O
which O
could O
induce O
apoptosis O
, O
increased O
the O
activation O
of O
PPARgamma O
in O
synovial O
cells O
. O
Furthermore O
, O
the O
ability O
of O
NSAIDs O
and O
PPARgamma O

ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma O
correlated O
with O

N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
incorporation O
and O
by O
4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene O
disulfonate O
(WST-1) O
assay O
, O
respectively O
. O
The O
apoptosis O
of O
synovial O
cells O
was O
identified O
by O
DNA O
fragmentation O
assay O
and O
terminal O

deoxynucleotidyl O
transferase-mediated O
dUTP O
nick-end O
labeling O
assay O
. O
Indometacin O
, O
diclofenac O
, O
oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
(NS-398) O
, O
a O
selective O
cyclooxygenase-2 O
inhibitor O
, O
also O

inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O
apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O
, O
and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
by O
4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene O
disulfonate O
(WST-1) O
assay O
, O
respectively O
. O
The O
apoptosis O
of O
synovial O
cells O
was O
identified O
by O
DNA O
fragmentation O
assay O
and O
terminal O
deoxynucleotidyl O
transferase-mediated O
dUTP O
nick-end O
labeling O
assay O
. O
Indometacin O
, O
diclofenac O
, O

oxaprozin O
, O
and O
zaltoprofen O
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells O
, O
whereas O
ketoprofen O
and O
acetaminophen O
did O
not O
. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide O
( O
NS-398 O
O O
, O
a O
selective O
cyclooxygenase-2 O
inhibitor O
, O
also O
inhibited O
cell O
proliferation O
, O
whereas O
it O
did O
not O
cause O
apoptosis O
. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma O
mRNA O

and O
the O
PPARgamma O
ligands O
15-deoxy-Delta(12,14)-prostaglandin O
J(2) O
and O
troglitazone O
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells O
. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma O
ligands O
but O
also O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O

acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O

amino O
acids O
acts O
as O
PART-OF O
for O
what O
entity O
? O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O

was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian O
brain O
GAD O
with O
diabetes O
sera O
. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65 O
. O
METHODS O
: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 O
by O
production O
of O
3H-GABA O
from O

gamma-aminobutyric O
acid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O

potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

gamma-aminobutyric O
acid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O

potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

gamma-aminobutyric O
acid O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O

potent O
autoantigen O
in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
( O
GABA O
O O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
( O
GABA O
O O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

GABA O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
( O
GABA O
O O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O
(r) O
protein O
was O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O

glutamate O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic O
acid O
decarboxylase O
(rGAD67/65) O
expressed O
in O
yeast.BACKGROUND O
AND O
AIMS O
: O
Glutamic O
acid O
decarboxylase O
(GAD O
, O
EC O
4.1.1.15) O
catalyses O
the O
conversion O
of O
glutamate O
to O
gamma-aminobutyric O
acid O
(GABA) O
. O
The O
65 O
kDa O
isoform O
, O
GAD65 O
is O
a O
potent O
autoantigen O

in O
type O
1 O
diabetes O
, O
whereas O
GAD67 O
is O
not O
. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino O
acids O
1-101 O
of O
GAD67 O
to O
a O
human O
cDNA O
for O
amino O
acids O
96-585 O
of O
GAD65; O
the O
recombinant O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O

clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 O
inhibitors O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O

clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 O
inhibitors O

celecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O
clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 B
inhibitors O
celecoxib O
and O

rofecoxib O
. O
METHODS O
: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O
(FDA) O
Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
renal O
failure O
submitted O
to O
the O
FDA O
. O
A O
MEDLINE O
search O
of O
the O
English O
language O
literature O
was O
also O
performed O
to O
identify O
published O
cases O
of O
renal O
failure O
associated O

rofecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O
clearly O
established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 B
inhibitors O
celecoxib O
and O
rofecoxib O

METHODS O
: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O
(FDA) O
Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
renal O
failure O
submitted O
to O
the O
FDA O
. O
A O
MEDLINE O
search O
of O
the O
English O
language O
literature O
was O
also O
performed O
to O
identify O
published O
cases O
of O
renal O
failure O
associated O
with O
celecoxib O

Celecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O
clearly O

established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O

Celecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib O
and O
rofecoxib.OBJECTIVE O
: O
Celecoxib O
and O
rofecoxib O
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O
cyclo-oxygenase-2 O
(COX-2) O
isoenzyme O
at O
therapeutic O
concentrations O
. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B
inhibitors O
has O
not O
been O
clearly O

established O
. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O

dopamine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O

reinforce O
previous O
assumptions O
that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O
this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

dopamine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O

reinforce O
previous O
assumptions O
that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O
this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

dopamine O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O
reinforce O
previous O
assumptions O

that O
dopamine O
may O
interact O
with O
eicosanoid O
metabolism O
by O
means O
of O
D(2) O
receptor O
activation O
, O
and O
implicate O
an O
involvement O
of O
cPLA(2) O
and O
COX-2 O
in O
this O
effect O
. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced O
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) O
receptor O
function O
in O
vitro O
. O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
EC(50) O
of O
794 O
nM O
. O
The O
effect O
was O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
, O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O

(COX) O
inhibitor O
, O
indomethacin O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O

sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O

indomethacin O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
EC(50) O
of O
794 O
nM O
. O
The O
effect O
was O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
, O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O

(COX) O
inhibitor O
, O
indomethacin O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O

sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
, O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O

selective O
COX-2 O
inhibitor O
, O
NS-398 O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O

ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O

valeryl O
salicylate O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
inhibitor O
of O
intracellular O
Ca(2+) O
release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O
selective O
COX-2 B
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O

COX-1 B
inhibitor O
, O
valeryl O
salicylate O
Both O
the O
non-specific O
phospholipase O
A(2) O
inhibitor O
, O
quinacrine O
, O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O

the O
p3C O
vector O
only O
. O
The O

quinacrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O
COX-1 O
inhibitor O
, O
valeryl O
salicylate O
. O
Both O
the O
non-specific O
phospholipase O

A(2) O
inhibitor O
, O
quinacrine O
and O
an O
inhibitor O
of O
cPLA(2) O
and O
iPLA(2) O
, O
AACOF3 O
, O
counteracted O
the O
effect; O
in O
contrast O
, O
a O
selective O
iPLA(2) O
inhibitor O
, O
BEL O
, O
and O
a O
selective O
sPLA(2) O
inhibitor O
, O
TAPC O
, O
were O
ineffective O
. O
No O
effects O
of O
dopamine O
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only O
. O
The O
results O
reinforce O
previous O
assumptions O
that O
dopamine O
may O

eticlopride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
Pharmacol O
1998;124:1651-8] O
. O
In O
the O
present O
report O
, O
we O
show O
that O
dopamine O
, O
under O
the O
same O
conditions O
, O
also O
induces O
a O
concentration-dependent O
increase O
in O
the O
production O
of O
PGE(2) O
, O
with O
a O
maximal O
effect O
of O
235% O
at O
approximately O
100 O
microM O
, O
and O
with O
an O
EC(50) O
of O
794 O
nM O
. O
The O
effect O
was O
counteracted O
by O
the O
D(2) O
antagonist O
eticlopride O
pertussis O
toxin O
, O
the O
inhibitor O
of O
intracellular O
Ca(2+) O

release O
TMB-8 O
, O
incubation O
in O
Ca(2+)-free O
experimental O
medium O
, O
and O
PKC O
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA O
. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase O
(COX) O
inhibitor O
, O
indomethacin O
, O
and O
by O
the O
selective O
COX-2 O
inhibitor O
, O
NS-398 O
, O
but O
not O
by O
the O
specific O

prostaglandin O
E(2) O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Dopamine O
D(2) O
receptor-induced O
COX-2-mediated O
production O
of O
prostaglandin O
E(2 O
in O
D(2)-transfected O
Chinese O
hamster O
ovary O
cells O
without O
simultaneous O
administration O
of O
a O
Ca(2+)-mobilizing O
agent.We O
have O
earlier O
demonstrated O
that O
dopamine O
stimulates O
the O
liberation O
of O
the O
prostaglandin O
E(2) O
(PGE(2)) O
precursor O
, O
arachidonic O
acid O
, O
in O
Chinese O
hamster O
ovary O
cells O
transfected O
with O
the O

rat O
dopamine O
D(2) O
receptor O
(long O
isoform) O
, O
also O
without O
concomitant O
administration O
of O
a O

Minocycline O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
adult O
ischemic O
injury/stroke O
and O
neurodegenerative O
disease O
models O
. O
However O
, O
minocycline's O
neuroprotective O
effects O
have O
not O
been O
assessed O
after O
insults O
to O
the O
neonatal O
brain O
. O
We O
now O
report O
that O
minocycline O
administered O
either O
immediately O
before O
or O
immediately O
after O
a O
hypoxic-ischemic O
insult O
substantially O
blocks O
tissue O
damage O
in O
a O
rodent O
model O
of O
neonatal O
hypoxic-ischemic O
brain O
injury O
. O
Minocycline O
treatment O
prevents O
the O
formation O
of O

activated O
caspase-3 O
, O
a O
known O
effector O
of O
apoptosis O
, O
as O
well O
as O
the O
appearance O
of O
a O
calpain O
cleaved O
substrate O
, O
a O
marker O
of O
excitotoxic/necrotic O
cell O
death O
. O
To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
a O
systemic O
treatment O
that O
can O
be O
administered O
after O
a O
hypoxic-ischemic O
insult O
, O
which O

Minocycline O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
adult O
ischemic O
injury/stroke O
and O
neurodegenerative O
disease O
models O
. O
However O
, O
minocycline's O
neuroprotective O
effects O
have O
not O
been O
assessed O
after O
insults O
to O
the O
neonatal O
brain O
. O
We O
now O
report O
that O
minocycline O
administered O
either O
immediately O
before O
or O
immediately O
after O
a O
hypoxic-ischemic O
insult O
substantially O
blocks O
tissue O
damage O
in O
a O
rodent O
model O
of O
neonatal O
hypoxic-ischemic O
brain O
injury O
. O
Minocycline O
treatment O
prevents O
the O

formation O
of O
activated O
caspase-3 O
, O
a O
known O
effector O
of O
apoptosis O
, O
as O
well O
as O
the O
appearance O
of O
a O
calpain O
cleaved O
substrate O
, O
a O
marker O
of O
excitotoxic/necrotic O
cell O
death O
. O
To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
a O
systemic O
treatment O
that O
can O
be O
administered O
after O
a O
hypoxic-ischemic O
insult O
, O
which O

mexiletine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
A O
novel O
SCN5A B
arrhythmia O
mutation O
, O
M1766L O
, O
with O
expression O
defect O
rescued O
by O
mexiletin O
.OBJECTIVE O
: O
Mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
, O
SCN5A O
, O
cause O
congenital O
long O
QT O
syndrome O
(LQT3) O
, O
Brugada O
syndrome O
, O
idiopathic O
ventricular O
fibrillation O
, O
and O
conduction O
disease O
by O
distinct O
cellular O
and O
clinical O
electrophysiological O
phenotypes O
. O
METHODS O

: O
Postmortem O
molecular O
analysis O
of O
SCN5A O
was O
conducted O
on O
an O
infant O
who O
presented O
shortly O
after O
birth O
with O
self-terminating O
torsades O

mexiletine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
A O
novel O
SCN5A B
arrhythmia O
mutation O
, O
M1766L O
, O
with O
expression O
defect O
rescued O
by O
mexiletin O
.OBJECTIVE O
: O
Mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
, O
SCN5A O
, O
cause O
congenital O
long O
QT O
syndrome O
(LQT3) O
, O
Brugada O
syndrome O
, O
idiopathic O
ventricular O
fibrillation O
, O
and O
conduction O
disease O
by O
distinct O
cellular O
and O
clinical O
electrophysiological O
phenotypes O
. O
METHODS O

: O
Postmortem O
molecular O
analysis O
of O
SCN5A O
was O
conducted O
on O
an O
infant O
who O
presented O
shortly O
after O
birth O
with O
self-terminating O
torsades O

sodium O
acts O
as O
UPREGULATOR O
for O
what O
entity O
? O
The O
M1766L O
mutation O
caused O
a O
significant O
decrease O
in O
the O
sodium O
channel O
expression O
. O
Co-expression O
with O
beta1 O
subunit O
, O
incubation O
at O
low O
temperature O
, O
and O
most O
effectively O
incubation O
with O
mexiletine O
partially O
'rescued' O
the O
defective O
expression O
. O
In O
addition O
to O
this O
pronounced O
loss O
of O
function O
, O
M1766L O
also O
showed O
a O
10-fold O
increase O
in O
the O
persistent O
late O
sodium O
current O
. O
CONCLUSIONS O
: O
These O
findings O
suggest O
that O
M1766L-SCN5A O
channel O
dysfunction O
may O
contribute O
to O
the O
basis O
of O

lethal O
arrhythmias O
, O
displays O
an O
overlapping O
electrophysiological O
phenotype O
, O
and O
represents O
the O
first O
sodium O
channelopathy O
rescued O
by O
drug O
. O

Valdecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Disposition O
of O
a O
specific O
cyclooxygenase-2 B
inhibitor O
, O
valdecoxib O
, O
in O
human O
. O
Valdecoxib O
is O
a O
potent O
and O
specific O
inhibitor O
of O
cyclooxygenase-2 O
, O
which O
is O
used O
for O
the O
treatment O
of O
rheumatoid O
arthritis O
, O
osteoarthritis O
, O
and O
the O
dysmenorrhea O
pain O
. O
Eight O
male O
human O
subjects O
each O
received O
a O
single O
50-mg O
oral O
dose O
of O
[(14)C]valdecoxib O
. O
Urine O
, O
feces O

, O
and O
blood O
samples O
were O
collected O
after O
administration O
of O
the O
radioactive O
dose O
. O
Most O

valdecoxib O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Disposition O
of O
a O
specific O
cyclooxygenase-2 B
inhibitor O
, O
valdecoxi O
O O
, O
in O
human.Valdecoxib O
is O
a O
potent O
and O
specific O
inhibitor O
of O
cyclooxygenase-2 O
, O
which O
is O
used O
for O
the O
treatment O
of O
rheumatoid O
arthritis O
, O
osteoarthritis O
, O
and O
the O
dysmenorrhea O
pain O
. O
Eight O
male O
human O
subjects O
each O
received O
a O
single O
50-mg O
oral O
dose O
of O
[(14)C]valdecoxib O
. O
Urine O
, O
feces O

and O
blood O
samples O
were O
collected O
after O
administration O
of O
the O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
= O
1.27 O
microM) O
and O
nicotine-evoked O
[(3)H]NE O
overflow O
(IC(50) O
= O
323 O
nM) O
at O
bupropion O
concentrations O
well O
below O
those O
eliciting O
intrinsic O
activity O
. O
Results O
from O
Schild O
analyses O
suggest O
that O
bupropion O
competitively O
inhibits O
nicotine-evoked O
[(3)H]DA O
overflow O
, O
whereas O
evidence O
for O
receptor O
reserve O
was O
obtained O
upon O
assessment O
of O
bupropion O
inhibition O
of O
nicotine-evoked O
[(3)H]NE O
overflow O
. O

Thus O
, O
bupropion O
acts O
as O
an O
antagonist O
at O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
in O
rat O
striatum O
and O
hippocampus O
, O
respectively O
, O
across O
the O
same O
concentration O
range O
that O
inhibits O
DAT O
and O
NET O
function O
. O
The O
combination O
of O
nAChR O
and O
transporter O
inhibition O
produced O
by O
bupropion O
may O
contribute O
to O
its O
clinical O
efficacy O
as O
a O
smoking O
cessation O
agent O
. O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
= O
1.27 O
microM) O
and O
nicotine-evoked O
[(3)H]NE O
overflow O
(IC(50) O
= O
323 O
nM) O
at O
bupropion O
concentrations O
well O
below O
those O
eliciting O
intrinsic O
activity O
. O
Results O
from O
Schild O
analyses O
suggest O
that O
bupropion O
competitively O
inhibits O
nicotine-evoked O
[(3)H]DA O
overflow O
, O
whereas O
evidence O
for O
receptor O
reserve O
was O
obtained O
upon O
assessment O
of O
bupropion O
inhibition O
of O
nicotine-evoked O
[(3)H]NE O
overflow O
. O

Thus O
, O
bupropion O
acts O
as O
an O
antagonist O
at O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
in O
rat O
striatum O
and O
hippocampus O
, O
respectively O
, O
across O
the O
same O
concentration O
range O
that O
inhibits O
DAT O
and O
NET O
function O
. O
The O
combination O
of O
nAChR O
and O
transporter O
inhibition O
produced O
by O
bupropion O
may O
contribute O
to O
its O
clinical O
efficacy O
as O
a O
smoking O
cessation O
agent O
. O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
reserve O
was O
obtained O
upon O
assessment O
of O
bupropion O
inhibition O
of O
nicotine-evoked O
[(3)H]NE O
overflow O
. O
Thus O
, O
bupropion O
acts O
as O
an O
antagonist O
at O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
in O
rat O
striatum O
and O
hippocampus O
, O
respectively O
, O
across O
the O
same O
concentration O
range O
that O
inhibits O
DAT O
and O
NET O
function O
. O
The O
combination O
of O
nAChR O
and O
transporter O
inhibition O
produced O
by O
bupropion O
may O
contribute O
to O
its O
clinical O
efficacy O
as O
a O

smoking O
cessation O
agent O
. O

Bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Bupropion O
inhibits O
nicotine-evoked O
[(3)H]overflow O
from O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
and O
from O
rat O
hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine O
. O
Bupropion O
an O
efficacious O
antidepressant O
and O
smoking O
cessation O
agent O
, O
inhibits O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
. O
Recently O
, O
bupropion O
has O
been O

reported O
to O
noncompetitively O
inhibit O
alpha3beta2 O
, O
alpha3beta4 O
, O
and O
alpha4beta2 O
nicotinic O
acetylcholine O
receptors O
(nAChRs) O
expressed O
in O
Xenopus O
oocytes O
or O
established O
cell O
lines O
. O
The O
present O
study O
evaluated O
bupropion-induced O
inhibition O
of O
native O
alpha3beta2* O

Bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Bupropion O
inhibits O
nicotine-evoked O
[(3)H]overflow O
from O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
and O
from O
rat O
hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine O
. O
Bupropion O
an O
efficacious O
antidepressant O
and O
smoking O
cessation O
agent O
, O
inhibits O
dopamine O
and O
norepinephrine O
transporters O
(DAT O
and O
NET O
, O
respectively) O
. O
Recently O
, O
bupropion O
has O
been O

reported O
to O
noncompetitively O
inhibit O
alpha3beta2 O
, O
alpha3beta4 O
, O
and O
alpha4beta2 O
nicotinic O
acetylcholine O
receptors O
(nAChRs) O
expressed O
in O
Xenopus O
oocytes O
or O
established O
cell O
lines O
. O
The O
present O
study O
evaluated O
bupropion-induced O
inhibition O
of O
native O
alpha3beta2* O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
evaluated O
bupropion-induced O
inhibition O
of O
native O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
using O
functional O
neurotransmitter O
release O
assays O
, O
nicotine-evoked O
[(3)H]overflow O
from O
superfused O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
([(3)H]DA) O
, O
and O
nicotine-evoked O
[(3)H]overflow O
from O
hippocampal O
slices O
preloaded O
with O

[(3)H]norepinephrine O
([(3)H]NE) O
. O
The O
mechanism O
of O
inhibition O
was O
evaluated O
using O
Schild O
analysis O
. O
To O
eliminate O
the O
interaction O
of O
bupropion O
with O
DAT O
or O
NET O
, O
nomifensine O
or O
desipramine O
, O
respectively O
, O
was O
included O
in O
the O
superfusion O
buffer O
. O
A O
high O
bupropion O
concentration O
(100 O
microM) O
elicited O
intrinsic O
activity O
in O
the O
[(3)H]DA O
release O
assay O
. O
However O
, O
none O
of O
the O
concentrations O
(1 O
nM-100 O
microM) O
examined O
evoked O
[(3)H]NE O

overflow O
and O
, O
thus O
, O
were O
without O
intrinsic O
activity O
in O
this O
assay O
. O

bupropion O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
evaluated O
bupropion-induced O
inhibition O
of O
native O
alpha3beta2* O
and O
alpha3beta4* O
nAChRs O
using O
functional O
neurotransmitter O
release O
assays O
, O
nicotine-evoked O
[(3)H]overflow O
from O
superfused O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine O
([(3)H]DA) O
, O
and O
nicotine-evoked O
[(3)H]overflow O
from O
hippocampal O
slices O
preloaded O
with O

[(3)H]norepinephrine O
([(3)H]NE) O
. O
The O
mechanism O
of O
inhibition O
was O
evaluated O
using O
Schild O
analysis O
. O
To O
eliminate O
the O
interaction O
of O
bupropion O
with O
DAT O
or O
NET O
, O
nomifensine O
or O
desipramine O
, O
respectively O
, O
was O
included O
in O
the O
superfusion O
buffer O
. O
A O
high O
bupropion O
concentration O
(100 O
microM) O
elicited O
intrinsic O
activity O
in O
the O
[(3)H]DA O
release O
assay O
. O
However O
, O
none O
of O
the O
concentrations O
(1 O
nM-100 O
microM) O
examined O
evoked O
[(3)H]NE O

overflow O
and O
, O
thus O
, O
were O
without O
intrinsic O
activity O
in O
this O
assay O
. O

Eprosartan O
acts O
as O
NOT O
for O
what O
entity O
? O
Within O
the O
class O
of O
angiotensin O
II O
antagonists O
, O
eprosartan O
differs O
from O
other O
currently O
clinically O
available O
agents O
in O
terms O
of O
its O
chemical O
structure O
and O
its O
dual O
pharmacological O
mode O
of O
action O
. O
Eprosartan O
acts O
not O
only O
at O
vascular O
AT1 O
receptors O
but O
also O
at O
presynaptic O
AT1 O
receptors O
, O
causing O
inhibition O
of O
sympathetically O
stimulated O
noradrenaline O
release O
. O
Eprosartan O
is O
not O
metabolized O
by O
cytochrome O
P450 O
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
, O

which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O
on O
multiple O
drugs O
. O
In O
clinical O
trials O
eprosartan O
has O
proven O
to O
be O
at O
least O
as O
effective O
as O
the O
ACE O
inhibitor O
enalapril O
in O

angiotensin O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
The O
clinical O
profile O
of O
the O
angiotensin O
II O
receptor O
blocker O
eprosartan.Angiotensin O
II O
receptor O
antagonists O
block O
angiotensin O
II O
type O
1 O
(AT1) O
receptors O
and O
reduce O
the O
pressor O
effects O
of O
angiotensin O
in O
the O
vasculature O
. O
By O
this O
mechanism O
, O
they O
induce O
similar O
pharmacological O
effects O
to O
angiotensin-converting O
enzyme O
(ACE) O
inhibitors O
, O
resulting O
in O
a O
lowering O
of O
blood O
pressure O
(BP) O
. O
However O
, O
AT1 O
antagonists O
differ O
from O
ACE O

inhibitors O
with O
respect O
to O
side O
effects O
, O
and O
induce O
less O
cough O
, O
which O
is O
related O
to O
bradykinin O
activation O
. O
Within O
the O
class O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
AT1 B
antagonists O
differ O
from O
ACE O
inhibitors O
with O
respect O
to O
side O
effects O
, O
and O
induce O
less O
cough O
, O
which O
is O
related O
to O
bradykinin O
activation O
. O
Within O
the O
class O
of O
angiotensin O
II O
antagonists O
, O
eprosartan O
differs O
from O
other O
currently O
clinically O
available O
agents O
in O
terms O
of O
its O
chemical O
structure O
and O
its O
dual O
pharmacological O
mode O
of O
action O
. O
Eprosartan O
acts O
not O
only O
at O
vascular O
AT1 O
receptors O
but O
also O
at O
presynaptic O
AT1 O
receptors O
, O
causing O
inhibition O
of O
sympathetically O

stimulated O
noradrenaline O
release O
. O
Eprosartan O
is O
not O
metabolized O
by O
cytochrome O
P450 O
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
, O
which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O

Eprosartan O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
AT1 B
antagonists O
differ O
from O
ACE O
inhibitors O
with O
respect O
to O
side O
effects O
, O
and O
induce O
less O
cough O
, O
which O
is O
related O
to O
bradykinin O
activation O
. O
Within O
the O
class O
of O
angiotensin O
II O
antagonists O
, O
eprosartan O
differs O
from O
other O
currently O
clinically O
available O
agents O
in O
terms O
of O
its O
chemical O
structure O
and O
its O
dual O
pharmacological O
mode O
of O
action O
. O
Eprosartan O
acts O
not O
only O
at O
vascular O
AT1 O
receptors O
but O
also O
at O
presynaptic O
AT1 O
receptors O
, O
causing O
inhibition O
of O
sympathetically O

stimulated O
noradrenaline O
release O
. O
Eprosartan O
is O
not O
metabolized O
by O
cytochrome O
P450 O
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
, O
which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O

eprosartan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
The O
clinical O
profile O
of O
the O
angiotensin O
II O
receptor O
blocker O
eprosarta O
.Angiotensin O
II O
receptor O
antagonists O
block O
angiotensin O
II O
type O
1 O
(AT1) O
receptors O
and O
reduce O
the O
pressor O
effects O
of O
angiotensin O
in O
the O
vasculature O
. O
By O
this O
mechanism O
, O
they O
induce O
similar O
pharmacological O
effects O
to O
angiotensin-converting O
enzyme O
(ACE) O
inhibitors O
, O
resulting O
in O
a O
lowering O
of O
blood O
pressure O
(BP) O
. O
However O
, O
AT1 O
antagonists O
differ O
from O
ACE O
inhibitors O

eprosartan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
receptors O
but O
also O
at O
presynaptic O
AT1 O
receptors O
, O
causing O
inhibition O
of O
sympathetically O
stimulated O
noradrenaline O
release O
. O
Eprosartan O
is O
not O
metabolized O
by O
cytochrome O
P450 O
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
, O
which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O
on O
multiple O
drugs O
. O
In O
clinical O
trials O
eprosartan O
has O
proven O
to O
be O
at O
least O
as O
effective O
as O
the O
ACE B
inhibitor O
enalapril O
in O
reducing O
BP O
, O
but O
with O
a O
significantly O
lower O

incidence O
of O
side O
effects O
. O
Eprosartan O
is O
safe O
, O
effective O
and O
well O
tolerated O
in O
long-term O
treatment O
, O
either O
as O
monotherapy O
or O
in O
combination O
with O
other O
antihypertensive O
drugs O
such O
as O
hydrochlorothiazide O
. O

BM O
acts O
as O
NOT O
for O
what O
entity O
? O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified- O
BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O

transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O

betamethasone-esters O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Species-specific O
differences O
in O
the O
glucocorticoid B
receptor I
transactivation O
function O
upon O
binding O
with O
betamethasone-ester O
.Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases O
. O
A O
number O
of O
adverse O
side O
effects O
, O
however O
, O
limit O
chronic O
treatment O
with O
GCs O
. O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O

, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O

BM O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O

cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O

DEX O
acts O
as O
AGONIST-ACTIVATOR O
for O
what O
entity O
? O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified- O
DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O

esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O

BM O
acts O
as O
AGONIST O
for O
what O
entity O
? O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O
BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified- O
BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O

transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O

BM O
acts O
as O
AGONIST O
for O
what O
entity O
? O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human O
and O
rat O
GR O
. O
Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified- O
BM O
mediated O
by O
rat O
GR O
, O
there O
were O
few O
side O
effects O
, O
evaluated O
by O
thymus O
involution O
and O
body O

weight O
loss O
, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats O
. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM O
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O

Dexamethasone O
acts O
as O
AGONIST O
for O
what O
entity O
? O
To O
improve O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O

transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O

DEX O
acts O
as O
AGONIST O
for O
what O
entity O
? O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
( O
DEX O
O O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O

agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O

betamethasone O
acts O
as O
AGONIST O
for O
what O
entity O
? O
their O
therapeutic O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O

agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O

BM O
acts O
as O
AGONIST O
for O
what O
entity O
? O
usefulness O
, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid O
receptor O
(GR) O
, O
transactivation O
and O
transrepression O
, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects O
, O
respectively O
. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
( O
BM O
O O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O

assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified-BM O
, O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O

BM O
acts O
as O
AGONIST O
for O
what O
entity O
? O
the O
transactivation O
response O
mediated O
by O
GR O
. O
Dexamethasone O
(DEX) O
, O
betamethasone O
(BM) O
, O
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human O
or O
rat O
GR O
. O
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O
transfected O
with O
human O
GR O
. O
The O
esterified- O
BM O
however O
, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat O
GR O
, O
whereas O

BM O
and O
esterified-DEX O
had O
full O
transactivation O
agonistic O
activity O
. O
Moreover O
, O
in O
rat O
hepatoma O
H4-II-E O
cells O
, O
the O
esterified-BM O
failed O
to O
induce O
tyrosine O
aminotransferase O
, O
which O
is O
regulated O
by O
GR-mediated O
transactivation O
activity O
. O
There O
were O
no O
significant O
differences O
between O
the O

pyridoxal O
phosphate O
acts O
as O
COFACTOR O
for O
what O
entity O
? O
sensing O
and O
substrate O
activation O
. O
In O
spite O
of O
their O
simple O
structures O
, O
biological O
[Fe-S] O
clusters O
are O
not O
formed O
spontaneously O
. O
Rather O
, O
a O
consortium O
of O
highly O
conserved O
proteins O
is O
required O
for O
both O
the O
formation O
of O
[Fe-S] O
clusters O
and O
their O
insertion O
into O
various O
protein O
partners O
. O
Among O
the O
[Fe-S] O
cluster O
biosynthetic O
proteins O
are O
included O
a O
pyridoxal O
phosphate O
dependent O
enzyme O
(NifS) O
that O
is O
involved O
in O
the O
activation O
of O
sulphur O
from O
l-cysteine O
, O

and O
a O
molecular O
scaffold O
protein O
(NifU) O
upon O
which O
[Fe-S] O
cluster O
precursors O
are O
formed O
. O
The O
formation O
or O
transfer O
of O
[Fe-S] O
clusters O
appears O
to O
require O
an O
electron-transfer O
step O
. O
Another O
complexity O
is O
that O
molecular O
chaperones O
homologous O
to O
DnaJ O
and O

l-cysteine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
are O
not O
formed O
spontaneously O
. O
Rather O
, O
a O
consortium O
of O
highly O
conserved O
proteins O
is O
required O
for O
both O
the O
formation O
of O
[Fe-S] O
clusters O
and O
their O
insertion O
into O
various O
protein O
partners O
. O
Among O
the O
[Fe-S] O
cluster O
biosynthetic O
proteins O
are O
included O
a O
pyridoxal O
phosphate-dependent O
enzyme O
(NifS) O
that O
is O
involved O
in O
the O
activation O
of O
sulphur O
from O
l-cysteine O
and O
a O
molecular O
scaffold O
protein O
(NifU) O
upon O
which O
[Fe-S] O
cluster O

precursors O
are O
formed O
. O
The O
formation O
or O
transfer O
of O
[Fe-S] O
clusters O
appears O
to O
require O
an O
electron-transfer O
step O
. O
Another O
complexity O
is O
that O
molecular O
chaperones O
homologous O
to O
DnaJ O
and O
DnaK O
are O
involved O
in O
some O
aspect O
of O
the O
maturation O
of O
[Fe-S]-cluster-containing O
proteins O
. O
It O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O

HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O

1.1 O
nM; O
SERT/DAT O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O

HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O

1.1 O
nM; O
SERT/DAT O

[(125)I] O
RTI-55 O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O

HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O

1.1 O
nM; O
SERT/DAT O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

4',7,8-trichloro O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O

on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O

cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O
(DAT O
K(i) O
= O
1.1 O
nM; O
SERT/DAT O
= O
1283 O
and O
NET/DAT O
= O
38) O
. O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT O
than O
the O
corresponding O
keto O
tautomers O
. O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O

mazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O

aryl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O

aryl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O

benzo O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O

benzo O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O

methoxy O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O

methoxy O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O

alkyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O

alkyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O

hydroxyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter I

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O

hydroxyl O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter I

(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O
HEK-hSERT O
, O
and O
HEK-hNET O

homomazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O

homomazindol O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamine O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O

transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O

5-HT O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O

, O
HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O

NE O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
, O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O

HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O
for O
HEK-hDAT O
cells O

dopamine O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
Mazindol O
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine O
binding O
site O
at O
the O
dopamin O
transporter.A O
series O
of O
mazindol O
(2) O
and O
homomazindol O
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl O
group O
and O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O

DA O
acts O
as O
SUBSTRATE O
for O
what O
entity O
? O
the O
benzo O
ring O
C O
, O
as O
well O
as O
H O
, O
methoxy O
, O
and O
alkyl O
groups O
replacing O
the O
hydroxyl O
group O
were O
synthesized O
, O
and O
their O
binding O
affinities O
at O
the O
dopamine O
transporter O
(DAT) O
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined O
. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA O
5-HT O
, O
and O
NE O
and O
inhibit O
binding O
of O
[(125)I] O
RTI-55 O
at O
HEK-hDAT O
, O

HEK-hSERT O
, O
and O
HEK-hNET O
cells O
. O
Mazindane O
(26) O
was O
found O
to O
be O
a O
pro-drug O
, O
oxidizing O
(5-H O
--> O
5-OH) O
to O
mazindol O
on O
rat O
striatal O
membranes O
and O
HEK-hDAT O
cells O
. O
The O
4',7,8-trichloro O
analogue O
(38) O
of O
mazindol O
was O
the O
most O
potent O
and O
selective O
ligand O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O

SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O
core O
of O
SUR O
with O
the O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O

K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O
core O
of O
SUR O
with O
the O
K(IR) O
pore O
. O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
SUR-dependent O
modulation O
of O
KATP B
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N O
and O
C-terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O

(P(O(max))) O
and O
attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O

C O
acts O
as O
PART-OF O
for O
what O
entity O
? O
SUR-dependent O
modulation O
of O
KATP O
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N- O
and O
C O
terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O

(P(O(max))) O
and O
attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O
did O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
Ctp O
and O
Rnp O
, O
a O
randomized O
Ntp O
, O
had O
no O
effect O
, O
indicating O
that O
the O
effects O
of O
Ntp O
are O
structure O
specific O
. O
Ntp O
opened O
K(IR)6.1/SUR1 O
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) O
and O
attenuated O
the O
coupling O
of O
high-affinity O
sulfonylurea O
binding O
with O
K(ATP) O
pore O
closure O
. O
These O
effects O
resemble O
those O
seen O
with O
N O
terminal O
deletions O
(DeltaN) O
of O

K(IR)6.0 O
, O
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) O
channels O
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP O
in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O

N O
acts O
as O
PART-OF O
for O
what O
entity O
? O
apparent O
IC(50) O
for O
ATP O
in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O
the O
channel O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O

glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O
(125)I-azidoglibenclamide O
, O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O

(125)I-azidoglibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O

(125)I-azidoglibenclamide O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O

(125)I-azidoglibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O

(125)I-azidoglibenclamide O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O

(125)I-azidoglibenclamide O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 O
are O
known O
to O
control O
the O
P(O(max)) O
. O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide O
binding O
, O
and O
DeltaNK(IR)6.2/SUR1 O
channels O
exhibit O
reduced O
labeling O
of O
K(IR) O
with O

(125)I-azidoglibenclamide O
implying O
that O
the O
K(IR) O
N O
terminus O
and O
L0 O
of O
SUR1 O
are O
in O
proximity O
. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) O
N O
terminus O
in O
ligand-inhibited O
K(ATP) O
channels O
and O
put O
forward O
a O
model O
, O
based O
on O
the O
architecture O
of O
BtuCD O
, O
MsbA O
, O
and O
the O
KcsA O
channel O
, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like O

sulfonylurea O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
that O
Ntp B
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times O
. O
Ctp O
and O
Rnp O
, O
a O
randomized O
Ntp O
, O
had O
no O
effect O
, O
indicating O
that O
the O
effects O
of O
Ntp O
are O
structure O
specific O
. O
Ntp O
opened O
K(IR)6.1/SUR1 O
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) O
and O
attenuated O
the O
coupling O
of O
high-affinity O
sulfonylurea O
binding O
with O

K(ATP) O
pore O
closure O
. O
These O
effects O
resemble O
those O
seen O
with O
N-terminal O
deletions O
(DeltaN) O
of O
K(IR)6.0 O
, O
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) O
channels O
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP O
in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O

ATP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N- O
and O
C-terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O
(P(O(max))) O
and O

attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O
did O
not O
affect O
significantly O
the O
mean O
open O
or O
"fast," O
K(+) O
driving O
force-dependent O
, O
intraburst O
closed O
times O
, O
verifying O
that O
Ntp O
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times O
. O
Ctp O
and O
Rnp O
, O
a O

ATP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
channels O
by O
an O
N-terminal O
KIR6.2 O
peptide O
. O
Defining O
intersubunit O
gating O
interactions.Ntp O
and O
Ctp O
, O
synthetic O
peptides O
based O
on O
the O
N- O
and O
C-terminal O
sequences O
of O
K(IR)6.0 O
, O
respectively O
, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR O
K(ATP) O
channels O
. O
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O
(P(O(max))) O
and O

attenuated O
the O
ATP O
inhibition O
of O
K(IR)6.2/SUR1 O
, O
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 O
channels O
. O
Ntp O
(up O
to O
approximately O
10(-4) O
m) O
did O
not O
affect O
significantly O
the O
mean O
open O
or O
"fast," O
K(+) O
driving O
force-dependent O
, O
intraburst O
closed O
times O
, O
verifying O
that O
Ntp O
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times O
. O
Ctp O
and O
Rnp O
, O
a O

ATP O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
opened O
K(IR)6.1/SUR1 O
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) O
and O
attenuated O
the O
coupling O
of O
high-affinity O
sulfonylurea O
binding O
with O
K(ATP) O
pore O
closure O
. O
These O
effects O
resemble O
those O
seen O
with O
N-terminal O
deletions O
(DeltaN) O
of O
K(IR)6.0 O
, O
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) O
channels O
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP O

in O
the O
absence O
of O
Mg(2+) O
. O
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N O
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O
the O
channel O
or O
with O
partial O
replacement O
of O
the O
deleted O
N O
terminus O
by O
Ntp O
, O
respectively O
. O
The O
K(IR) O
N O
terminus O
and O
the O

gemfibrozil O
acts O
as O
NOT O
for O
what O
entity O
? O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O

to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O
(GAS) O
, O
nuclear O
factor-kappaB O

(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O

gemfibrozil O
acts O
as O
NOT O
for O
what O
entity O
? O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O

NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O

gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O

inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O

DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O

gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O

inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O

DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O

gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O

gemfibrozil O
mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

iNOS O
promoter O
contains O

Gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O

gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O

Gemfibrozil O
acts O
as O
ACTIVATOR O
for O
what O
entity O
? O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O

gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O

gemfibrozil O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O

iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O

proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O

Gemfibrozil O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes O
. O
Gemfibrozil O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O

gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O

Gemfibrozil O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes O
. O
Gemfibrozil O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O

gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O

gemfibrozil O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O

to O
gemfibrozil O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O

clofibrate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O

gemfibrozil O
, O
clofibrate O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O

fibrate O
acts O
as O
INDIRECT-DOWNREGULATOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O

gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O

gemfibrozil-mediated O
inhibition O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O

iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O

(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O

in O
gemfibrozil O
mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O

iNOS O
promoter O
contains O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Since O
gemfibrozil O
is O
known O
to O
activate O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O

PPAR-alpha O
. O
However O
, O
DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil O
mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O

gamma-activation O
site O
(GAS) O
, O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
peroxisome O
proliferator-activated O
receptor-alpha O
(PPAR-alpha) O
, O
we O
investigated O
the O
role O
of O
PPAR-alpha O
in O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
. O
Gemfibrozil O
induced O
peroxisome O
proliferator-responsive O
element O
(PPRE)-dependent O
luciferase O
activity O
, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha O
, O
the O
dominant-negative O
mutant O
of O
human O
PPAR-alpha O
. O
However O
, O

DeltahPPAR-alpha O
was O
unable O
to O
abrogate O
gemfibrozil-mediated O
inhibition O
of O
iNOS O
suggesting O
that O
gemfibrozil O
inhibits O
iNOS O
independent O
of O
PPAR-alpha O
. O
The O
human O
iNOS O
promoter O
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors O
, O
including O
interferon-gamma O
(IFN-gamma) O
regulatory O
factor-1 O
(IRF-1) O
binding O
to O
interferon-stimulated O
responsive O
element O
(ISRE) O
, O
signal O
transducer O
and O
activator O
of O
transcription O
(STAT) O
binding O
to O
gamma-activation O
site O

(GAS) O
, O
nuclear O
factor-kappaB O
(NF-kappaB) O
, O
activator O
protein-1 O
(AP-1) O
, O
and O

Gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes O
. O
Gemfibrozil O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O

clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O

NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O

NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
investigated O
the O
effect O
of O
gemfibrozil O
on O
the O
activation O
of O
these O
transcription O
factors O
. O
The O
combination O
of O
interleukin O
(IL)-1beta O
and O
IFN-gamma O
induced O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O

NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O
results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O

results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O

results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O

results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

gemfibrozil O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
NF-kappaB O
, O
AP-1 O
, O
C/EBPbeta O
, O
and O
GAS O
but O
not O
that O
of O
ISRE O
, O
suggesting O
that O
IRF-1 O
may O
not O
be O
involved O
in O
cytokine-induced O
expression O
of O
iNOS O
in O
human O
astrocytes O
. O
Interestingly O
, O
gemfibrozil O
strongly O
inhibited O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated O
astroglial O
cells O
. O
These O

results O
suggest O
that O
gemfibrozil O
inhibits O
the O
induction O
of O
iNOS O
probably O
by O
inhibiting O
the O
activation O
of O
NF-kappaB O
, O
AP-1 O
, O
and O
C/EBPbeta O
and O
that O
gemfibrozil O
, O
a O
prescribed O
drug O
for O
humans O
, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases O
. O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O

clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O

NO O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O
, O

clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxid O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O

, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O

, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O

nitric-oxide O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibits O
the O
induction O
of O
nitric-oxide O
synthase O
in O
human O
astrocytes.Gemfibrozil O
, O
a O
lipid-lowering O
drug O
, O
inhibited O
cytokine-induced O
production O
of O
NO O
and O
the O
expression O
of O
inducible O
nitric-oxide O
synthase O
(iNOS) O
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes O
. O
Similar O
to O
gemfibrozil O

, O
clofibrate O
, O
another O
fibrate O
drug O
, O
also O
inhibited O
the O
expression O
of O
iNOS O
. O
Inhibition O
of O
human O
iNOS O
promoter-driven O
luciferase O
activity O
by O
gemfibrozil O
in O
cytokine-stimulated O
U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS O
. O
Since O
gemfibrozil O
is O

lisuride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride O
, O
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine O
receptors O
in O
considering O
its O
antiparkinsonian O
effects O
, O
or O
an O
exclusive O
role O
of O
5-HT(2A/2C) O
receptor O
activation O
in O
hallucinogenesis O
. O
These O
conclusions O
are O
surprising O
when O
one O
considers O
that O
the O
potent O
interaction O
of O
lisuride O
with O
5-HT(1A) O
receptors O
has O
been O
demonstrated O
in O
several O
different O
laboratories O
and O
that O
activation O
of O

5-HT(1A) O
and O
5-HT(1B) O
receptors O
can O
modulate O
dopaminergically O
mediated O
responses O
. O
OBJECTIVE O
: O
The O
lack O
of O
full O
substitution O
of O
lisuride O
for O
lysergic O
acid O
diethylamide O
(LSD) O
in O
drug O
discrimination O
experiments O
and O
induction O
of O
a O
pronounced O
5-HT O
syndrome O
by O
this O

lisuride O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Re-evaluation O
of O
lisuride O
pharmacology O
: O
5-hydroxytryptamine1A O
receptor-mediated O
behavioral O
effects O
overlap O
its O
other O
properties O
in O
rats.RATIONALE O
: O
There O
is O
substantial O
evidence O
that O
lisuride O
can O
produce O
effects O
linked O
to O
5-HT(1A) O
receptor O
occupancy O
. O
Nevertheless O
, O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride O
, O
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine B
receptors I
in O
considering O
its O
antiparkinsonian O
effects O
, O
or O

an O
exclusive O
role O
of O
5-HT(2A/2C) O
receptor O
activation O
in O
hallucinogenesis O
. O
These O
conclusions O
are O

lisuride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
Re-evaluation O
of O
lisuride O
pharmacology O
: O
5-hydroxytryptamine1A O
receptor-mediated O
behavioral O
effects O
overlap O
its O
other O
properties O
in O
rats.RATIONALE O
: O
There O
is O
substantial O
evidence O
that O
lisuride O
can O
produce O
effects O
linked O
to O
5-HT(1A) O
receptor O
occupancy O
. O
Nevertheless O
, O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride O
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine B
receptors I
in O
considering O
its O
antiparkinsonian O
effects O
, O
or O
an O
exclusive O
role O
of O

5-HT(2A/2C) O
receptor O
activation O
in O
hallucinogenesis O
. O
These O
conclusions O
are O
surprising O
when O
one O
considers O
that O
the O
potent O
interaction O
of O
lisuride O
with O
5-HT(1A) O
receptors O
has O
been O
demonstrated O
in O
several O
different O
laboratories O
and O
that O

lisuride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
dose O
dependently O
decreased O
body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O
of O
the O
selective O
5-HT(1A) O
agonist O
LY O
293284 O
. O
The O
hypothermic O
effect O
of O
lisuride O
was O
prevented O
by O
pre-injection O
of O
pMPPI O
, O
but O
not O
by O
ketanserin O
or O
haloperidol O
. O
CONCLUSION O
: O
We O
have O
demonstrated O
that O
the O
behavioral O
effects O
of O
low O
doses O
of O
lisuride O
are O
clearly O
mediated O
by O
stimulation O
of O
5-HT(1A) O
receptors O
. O

Lisuride O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
experiments O
that O
might O
explain O
the O
primary O
mechanism O
responsible O
for O
lisuride-mediated O
biological O
effects O
and O
its O
paradoxical O
classification O
as O
a O
dopamine O
agonist O
in O
the O
literature O
. O
RESULTS O
: O
In O
drug O
discrimination O
studies O
, O
lisuride O
fully O
mimicked O
the O
5-HT(1A) O
agonist O
LY O
293284 O
, O
only O
partially O
substituted O
for O
LSD O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O
(+)-amphetamine O
. O
Lisuride O
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O

, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O
Only O
pMPPI O
[4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride] O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O
effective O
in O
inhibiting O
all O
5-HT O
syndrome O
behaviors O
produced O
by O
lisuride O
, O
whereas O
pMPPI O
was O
without O

LY O
293284 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
Only O
pMPPI O
[4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride] O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O
effective O
in O
inhibiting O
all O
5-HT O
syndrome O
behaviors O
produced O
by O
lisuride O
, O
whereas O
pMPPI O
was O
without O
effect O
on O
any O
behavior O
induced O
by O
LSD O
. O
Lisuride O
dose O
dependently O
decreased O

body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O
of O
the O
selective O
5-HT(1A) O
agonist O
LY O
293284 O
The O
hypothermic O
effect O
of O
lisuride O
was O
prevented O
by O
pre-injection O
of O
pMPPI O
, O
but O
not O
by O
ketanserin O
or O
haloperidol O
. O
CONCLUSION O
: O
We O
have O
demonstrated O
that O
the O
behavioral O
effects O
of O
low O
doses O
of O
lisuride O
are O
clearly O
mediated O
by O
stimulation O
of O
5-HT(1A) O
receptors O
. O

lisuride O
acts O
as O
AGONIST O
for O
what O
entity O
? O
and O
induction O
of O
a O
pronounced O
5-HT O
syndrome O
by O
this O
compound O
at O
relatively O
low O
doses O
convinced O
us O
to O
execute O
two O
series O
of O
experiments O
that O
might O
explain O
the O
primary O
mechanism O
responsible O
for O
lisuride-mediated O
biological O
effects O
and O
its O
paradoxical O
classification O
as O
a O
dopamine O
agonist O
in O
the O
literature O
. O
RESULTS O
: O
In O
drug O
discrimination O
studies O
, O
lisuride O
fully O
mimicked O
the O
5-HT(1A) O
agonist O
LY O
293284 O
, O
only O
partially O
substituted O
for O
LSD O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O

(+)-amphetamine O
. O
Lisuride O
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O
, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O
Only O
pMPPI O

LY O
293284 O
acts O
as O
AGONIST O
for O
what O
entity O
? O
syndrome O
by O
this O
compound O
at O
relatively O
low O
doses O
convinced O
us O
to O
execute O
two O
series O
of O
experiments O
that O
might O
explain O
the O
primary O
mechanism O
responsible O
for O
lisuride-mediated O
biological O
effects O
and O
its O
paradoxical O
classification O
as O
a O
dopamine O
agonist O
in O
the O
literature O
. O
RESULTS O
: O
In O
drug O
discrimination O
studies O
, O
lisuride O
fully O
mimicked O
the O
5-HT(1A) O
agonist O
LY O
293284 O
only O
partially O
substituted O
for O
LSD O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O
(+)-amphetamine O
. O
Lisuride O
produced O

a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O
, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O
Only O
pMPPI O
[4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride] O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O

4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride O
acts O
as O
ANTAGONIST O
for O
what O
entity O
? O
mimicked O
the O
5-HT(1A) O
agonist O
LY O
293284 O
, O
only O
partially O
substituted O
for O
LSD O
and O
DOI O
, O
and O
failed O
to O
substitute O
for O
(+)-amphetamine O
. O
Lisuride O
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture O
, O
forepaw O
treading O
, O
and O

lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) O
receptors O
. O
Only O
pMPPI O
[ O
4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide O
hydrochloride O
O O
, O
a O
selective O
5-HT(1A) O
antagonist O
, O
was O
effective O
in O
inhibiting O
all O
5-HT O
syndrome O
behaviors O
produced O
by O
lisuride O
, O
whereas O
pMPPI O
was O
without O
effect O
on O

behavior O
induced O
by O
LSD O
. O
Lisuride O
dose O
dependently O
decreased O
body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O
of O
the O
selective O
5-HT(1A) O
agonist O
LY O
293284 O
. O
The O

HED O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
neurons O
in O
vivo O
. O
To O
extend O
structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine O
transporters O
and O
to O
determine O
which O
stereoisomer O
displayed O
the O
best O
selectivity O
for O
PET O
imaging O
applications O
, O
we O
tested O
the O
HED O
compounds O
for O
their O
abilities O
to O
inhibit O
[(3)H]neurotransmitter O
uptake O
into O
platelets O
, O
transfected O
cells O
, O
and O
chromaffin O
vesicles O
. O
We O
hypothesized O
that O
the O
HED O
compounds O
would O
be O
most O
potent O
at O
the O
norepinephrine O
transporter O
(NET) O
compared O
to O
the O
serotonin O
or O

dopamine O
transporters O
and O
that O
the O
1R O
diastereomers O
would O
be O
more O
effective O
than O
1S O
diastereomers O
. O
Supporting O
the O
hypotheses O
, O
all O
stereoisomers O
were O
most O
potent O
at O
the O
NET O
and O
the O
1R,2S O
stereoisomer O
was O
the O
most O
potent O
inhibitor O

HED O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
neurons O
in O
vivo O
. O
To O
extend O
structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine O
transporters O
and O
to O
determine O
which O
stereoisomer O
displayed O
the O
best O
selectivity O
for O
PET O
imaging O
applications O
, O
we O
tested O
the O
HED O
compounds O
for O
their O
abilities O
to O
inhibit O
[(3)H]neurotransmitter O
uptake O
into O
platelets O
, O
transfected O
cells O
, O
and O
chromaffin O
vesicles O
. O
We O
hypothesized O
that O
the O
HED O
compounds O
would O
be O
most O
potent O
at O
the O
norepinephrine O
transporter O
(NET) O
compared O
to O
the O
serotonin O
or O

dopamine O
transporters O
and O
that O
the O
1R O
diastereomers O
would O
be O
more O
effective O
than O
1S O
diastereomers O
. O
Supporting O
the O
hypotheses O
, O
all O
stereoisomers O
were O
most O
potent O
at O
the O
NET O
and O
the O
1R,2S O
stereoisomer O
was O
the O
most O
potent O
inhibitor O

meta-hydroxyephedrine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Stereospecific O
inhibition O
of O
monoamine O
uptake O
transporters O
by O
meta-hydroxyephedrin O
isomers.Meta-hydroxyephedrine O
(HED) O
comprises O
four O
stereoisomers O
consisting O
of O
two O
enantiomeric O
pairs O
related O
to O
ephedrine O
and O
pseudoephedrine O
. O
HED O
is O
transported O
into O
adrenergic O
neurons O
and O
radiolabeled O
HED O
has O
been O
employed O
in O
positron O
emission O
tomography O
(PET) O
to O
image O
adrenergic O
neurons O
in O
vivo O
. O
To O
extend O

structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine O
transporters O
and O

HED O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
HED O
is O
transported O
into O
adrenergic O
neurons O
and O
radiolabeled O
HED O
has O
been O
employed O
in O
positron O
emission O
tomography O
(PET) O
to O
image O
adrenergic O
neurons O
in O
vivo O
. O
To O
extend O
structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine O
transporters O
and O
to O
determine O
which O
stereoisomer O
displayed O
the O
best O
selectivity O
for O
PET B
imaging O
applications O
, O
we O
tested O
the O
HED O
compounds O
for O
their O
abilities O
to O
inhibit O
[(3)H]neurotransmitter O
uptake O
into O
platelets O
, O
transfected O
cells O
, O
and O
chromaffin O

vesicles O
. O
We O
hypothesized O
that O
the O
HED O
compounds O
would O
be O
most O
potent O
at O
the O
norepinephrine O
transporter O
(NET) O
compared O
to O
the O
serotonin O
or O
dopamine O
transporters O
and O
that O
the O
1R O
diastereomers O
would O
be O
more O
effective O
than O
1S O
diastereomers O
. O

escitalopram O
acts O
as O
NOT O
for O
what O
entity O
? O
high O
affinity O
to O
the O
human O
serotonin O
transporter O
. O
Conversely O
, O
R-citalopram O
is O
approximately O
30-fold O
less O
potent O
than O
escitalopram O
at O
this O
transporter O
. O
Escitalopram O
has O
linear O
pharmacokinetics O
, O
so O
that O
plasma O
levels O
increase O
proportionately O
and O
predictably O
with O
increased O
doses O
and O
its O
half-life O
of O
27 O
- O
32 O
h O
is O
consistent O
with O
once-daily O
dosing O
. O
In O
addition O
, O
escitalopram O
has O
negligible O
effects O
on O
cytochrome O
P450 O
drug-metabolising O
enzymes O

in O
vitro O
, O
suggesting O
a O
low O
potential O
for O
drug-drug O
interactions O
. O
The O
efficacy O
of O
escitalopram O
in O
patients O
with O
major O
depressive O
disorder O
has O
been O
demonstrated O
in O
multiple O
short-term O
, O
placebo-controlled O
clinical O
trials O
, O
three O
of O
which O
included O
citalopram O
as O
an O
active O
control O
, O
as O
well O
as O
in O

escitalopram O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
Escitalopram.Escitalopram O
oxalate O
(S-citalopram O
, O
Lexapro) O
, O
a O
selective O
serotonin B
re-uptake O
inhibitor O
antidepressant O
which O
is O
the O
S-enantiomer O
of O
citalopram O
, O
is O
in O
clinical O
development O
worldwide O
for O
the O
treatment O
of O
depression O
and O
anxiety O
disorders O
. O
Preclinical O
studies O
demonstrate O
that O
the O
therapeutic O
activity O
of O
citalopram O
resides O
in O
the O
S-isomer O
and O
that O
escitalopram O
binds O
with O
high O
affinity O
to O

the O
human O
serotonin O
transporter O
. O
Conversely O
, O
R-citalopram O
is O
approximately O
30-fold O
less O
potent O
than O
escitalopram O
at O
this O
transporter O
. O
Escitalopram O
has O
linear O
pharmacokinetics O
, O
so O
that O
plasma O
levels O
increase O
proportionately O
and O
predictably O
with O
increased O
doses O
and O
its O
half-life O
of O
27 O
- O
32 O
h O
is O
consistent O
with O
once-daily O
dosing O
. O

NH(2) O
acts O
as O
PART-OF O
for O
what O
entity O
? O
and O
with O
rhodamine O
B O
(characteristics O
of O
MBs O
formed O
in O
vivo) O
, O
eventually O
leading O
to O
cell O
death O
. O
The O
MB-like O
aggregates O
were O
deposited O
around O
centrosomes O
and O
disrupted O
the O
microtubular O
array O
. O
Coexpression O
of O
K8 O
with O
K18 B
restored O
the O
normal O
fibrous O
pattern O
of O
keratin O
distribution O
and O
reduced O
the O
toxicity O
of O
K18 O
. O
In O
contrast O
, O
an O
NH(2) O
terminal O
deletion O
mutant O
of O
K8 O
promoted O
the O
formation O
of O
intracellular O
aggregates O
even O
in O
the O
absence O
of O
K18 O
overexpression O
. O

Deregulated O
expression O
of O
K18 O
, O
or O
an O
imbalance O
between O
K8 O
and O
K18 O
, O
may O
thus O
be O
an O
important O
determinant O
of O
MB O
formation O
, O
which O
compromises O
the O
function O
of O
centrosomes O
and O
the O
microtubule O
network O
and O

griseofulvin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
individuals O
with O
alcoholic O
liver O
disease O
, O
nonalcoholic O
steatohepatitis O
, O
or O
benign O
or O
malignant O
hepatocellular O
neoplasia O
. O
Mice O
fed O
long O
term O
with O
griseofulvin O
are O
an O
animal O
model O
of O
MB O
formation O
. O
However O
, O
the O
lack O
of O
a O
cellular O
model O
has O
impeded O
understanding O
of O
the O
molecular O
mechanism O
of O
this O
process O
. O
Culture O
of O
HepG2 O
cells O
with O
griseofulvin O
has O
now O
been O
shown O
to O
induce O
both O
the O
formation O
of O
intracellular O
aggregates O
containing O
K18 O

as O
well O
as O
an O
increase O
in O
the O
abundance O
of O
K18 O
mRNA O
. O
Overexpression O
of O
K18 O
in O
HepG2 O
, O
HeLa O
, O
or O
COS-7 O
cells O
also O
induced O
the O
formation O
of O
intracellular O
aggregates O
that O
stained O
with O
antibodies O
to O
ubiquitin O
and O
with O

griseofulvin O
acts O
as O
INDIRECT-UPREGULATOR O
for O
what O
entity O
? O
of O
individuals O
with O
alcoholic O
liver O
disease O
, O
nonalcoholic O
steatohepatitis O
, O
or O
benign O
or O
malignant O
hepatocellular O
neoplasia O
. O
Mice O
fed O
long O
term O
with O
griseofulvin O
are O
an O
animal O
model O
of O
MB O
formation O
. O
However O
, O
the O
lack O
of O
a O
cellular O
model O
has O
impeded O
understanding O
of O
the O
molecular O
mechanism O
of O
this O
process O
. O
Culture O
of O
HepG2 O
cells O
with O
griseofulvin O
has O
now O
been O
shown O
to O
induce O
both O
the O
formation O
of O
intracellular O
aggregates O
containing O
K18 O

as O
well O
as O
an O
increase O
in O
the O
abundance O
of O
K18 O
mRNA O
. O
Overexpression O
of O
K18 O
in O
HepG2 O
, O
HeLa O
, O
or O
COS-7 O
cells O
also O
induced O
the O
formation O
of O
intracellular O
aggregates O
that O
stained O
with O
antibodies O
to O
ubiquitin O
and O
with O

REV O
5901 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 B
inhibitor O
indomethacin; O
the O
COX-2 B
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O

flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901 O
and O
the O
5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
. O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O
inhibitors O
. O
The O
data O
suggest O
that O
both O
COX O
inhibitors O
and O
5-LOX O
inhibitors O
may O
be O
neuroprotective O
in O

MK-886 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O

5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O
inhibitors O
. O
The O
data O
suggest O
that O
both O
COX O
inhibitors O
and O
5-LOX O
inhibitors O
may O
be O
neuroprotective O
in O
vivo O
by O
suppressing O
toxic O
actions O
of O
microglia/macrophages O
, O
and O

MK-886 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O

5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O
inhibitors O
. O
The O
data O
suggest O
that O
both O
COX O
inhibitors O
and O
5-LOX O
inhibitors O
may O
be O
neuroprotective O
in O
vivo O
by O
suppressing O
toxic O
actions O
of O
microglia/macrophages O
, O
and O

NS-398 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
of O
the O
cyclooxygenase O
(COX) O
or O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX O
pathway O
generates O
inflammatory O
prostaglandins O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 B
inhibitor O

indomethacin; O
the O
COX-2 O
inhibitor O
NS-398 O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O
5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
. O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O

5-LOX O
inhibitors O

ibuprofen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX O
pathway O
generates O
inflammatory O
prostaglandins O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 B
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O

NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O
5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
. O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O

ibuprofen O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX O
pathway O
generates O
inflammatory O
prostaglandins O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 B
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O

NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O
5-LOX O
activating O
protein O
(FLAP) O
inhibitor O
MK-886 O
. O
The O
FLAP O
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin O
. O
Combinations O
of O
COX O
and O
5-LOX O
inhibitors O
were O
more O
effective O
than O
single O

prostaglandins O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cells O
are O
cultured O
in O
supernatants O
from O
activated O
cells O
of O
the O
human O
monocytic O
THP-1 O
line O
and O
their O
survival O
is O
followed O
. O
Respiratory O
burst O
is O
directly O
measured O
on O
the O
activated O
cells O
. O
We O
tested O
inhibitors O
of O
the O
cyclooxygenase O
(COX) O
or O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX B
pathway O
generates O
inflammatory O
prostaglandins O
while O
the O
5-LOX O
pathway O
generates O

inflammatory O
leukotrienes O
. O
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O

leukotrienes O
acts O
as O
PRODUCT-OF O
for O
what O
entity O
? O
cells O
of O
the O
human O
monocytic O
THP-1 O
line O
and O
their O
survival O
is O
followed O
. O
Respiratory O
burst O
is O
directly O
measured O
on O
the O
activated O
cells O
. O
We O
tested O
inhibitors O
of O
the O
cyclooxygenase O
(COX) O
or O
the O
5-lipoxygenase O
(5-LOX) O
pathways O
as O
possible O
neuroprotective O
agents O
. O
The O
COX B
pathway O
generates O
inflammatory O
prostaglandins O
, O
while O
the O
5-LOX O
pathway O
generates O
inflammatory O
leukotrienes O
We O
found O

that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion O
. O
They O
included O
the O
COX-1 O
inhibitor O
indomethacin; O
the O
COX-2 O
inhibitor O
NS-398; O
the O
mixed O
COX-1/COX-2 O
inhibitor O
ibuprofen; O
the O
nitric O
oxide O
(NO) O
derivatives O
of O
indomethacin O
, O
ibuprofen O
and O
flurbiprofen; O
the O
5-LOX O
inhibitor O
REV O
5901; O
and O
the O
5-LOX O
activating O
protein O

p-chlorophenylalanine O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O

, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA-induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O

MDMA O
acts O
as O
REGULATOR O
for O
what O
entity O
? O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT B
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O

and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA-induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
in O
SERT B
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O
MDMA O
induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin O
, O
but O
may O
occur O
in O
response O
to O
some O

other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA O
. O

serotonin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O

p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O

serotonin O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O

p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O

3,4-methylenedioxymethamphetamine O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O

SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
MDMA- O
and O
p-chlorophenylalanine-induced O
reduction O
in O
5-HT O
concentrations O
: O
effects O
on O
serotonin O
transporter O
densities.Low O
levels O
of O
serotonin O
may O
reduce O
the O
density O
of O
the O
serotonin O
transporter O
(SERT) O
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
( O
MDMA O
-induced O
reductions O
in O
SERT O
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O

p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O

MDMA O
acts O
as O
DOWNREGULATOR O
for O
what O
entity O
? O
"neuroadaptive O
response" O
. O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine O
(MDMA)-induced O
reductions O
in O
SERT B
density O
could O
be O
related O
to O
such O
a O
mechanism O
, O
p-chlorophenylalanine O
or O
MDMA O
was O
administered O
to O
rats O
, O
and O
brain O
serotonin O
and O
SERT O
density O
were O
measured O
. O
As O
expected O
, O
both O
treatments O
led O
to O
serotonin O
depletion O
1 O
, O
7 O
and O
14 O
days O
later O
. O
However O
, O
only O
MDMA O
reduced O
SERT O
density O
. O
This O
observation O
suggests O
that O

MDMA-induced O
reductions O
in O
SERT O
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin O
, O
but O
may O
occur O
in O
response O
to O
some O
other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA O
. O

atomoxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine B
(NE) O
transporter I
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O

atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O
NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O
transporters O
with O
dissociation O
constants O
(K(i)) O
values O
of O
5 O
, O
77 O

Atomoxetine O
acts O
as O
DIRECT-REGULATOR O
for O
what O
entity O
? O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O

NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O
transporters O
with O
dissociation O
constants O
(K(i)) O
values O
of O
5 O
, O
77 O
and O
1451 O
nM O
, O
respectively O
, O
demonstrating O
selectivity O
for O
NE O
transporters O
. O
In O
microdialysis O
studies O
, O
atomoxetine O
increased O
extracellular O
(EX) O
levels O
of O
NE O
in O
prefrontal O
cortex O
(PFC) O

atomoxetine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine B
(NE) O
transporter I
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O

atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O
Atomoxetine O
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human O
NE O
, O
serotonin O
(5-HT) O
and O
dopamine O
(DA) O
transporters O
with O
dissociation O
constants O
(K(i)) O
values O
of O
5 O
, O
77 O

atomoxetine O
acts O
as O
INDIRECT-REGULATOR O
for O
what O
entity O
? O
or O
nucleus O
accumbens O
. O
In O
contrast O
, O
the O
psychostimulant O
methylphenidate O
, O
which O
is O
used O
in O
ADHD O
therapy O
, O
increased O
NE(EX) O
and O
DA(EX) O
equally O
in O
PFC O
, O
but O
also O
increased O
DA(EX) O
in O
the O
striatum O
and O
nucleus O
accumbens O
to O
the O
same O
level O
. O
The O
expression O
of O
the O
neuronal O
activity O
marker O
Fos B
was O
increased O
3.7-fold O
in O
PFC O
by O
atomoxetine O
administration O
, O
but O
was O
not O
increased O
in O
the O
striatum O
or O
nucleus O

accumbens O
, O
consistent O
with O
the O
regional O
distribution O
of O
increased O
DA(EX) O
. O
We O
hypothesize O
that O
the O
atomoxetine-induced O
increase O
of O
catecholamines O
in O
PFC O
, O
a O
region O
involved O
in O
attention O
and O
memory O
, O
mediates O
the O
therapeutic O
effects O
of O
atomoxetine O
in O
ADHD O
. O
In O
contrast O
to O
methylphenidate O
, O
atomoxetine O

atomoxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Atomoxetine O
increases O
extracellular O
levels O
of O
norepinephrine O
and O
dopamine O
in O
prefrontal O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine B
(NE) I
transporter I
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O

action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O

tomoxetine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Atomoxetine O
increases O
extracellular O
levels O
of O
norepinephrine O
and O
dopamine O
in O
prefrontal O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine B
(NE) I
transporter I
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603) O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O
of O

action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O

LY139603 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Atomoxetine O
increases O
extracellular O
levels O
of O
norepinephrine O
and O
dopamine O
in O
prefrontal O
cortex O
of O
rat O
: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder.The O
selective O
norepinephrine B
(NE) I
transporter I
inhibitor O
atomoxetine O
(formerly O
called O
tomoxetine O
or O
LY139603 O
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O
Deficit/Hyperactivity O
Disorder O
(ADHD) O
. O
We O
investigated O
the O
mechanism O

of O
action O
of O
atomoxetine O
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine O
with O
monoamine O
transporters O
, O
the O
effects O
on O
extracellular O
levels O
of O
monoamines O
, O
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos O
in O
brain O
regions O
. O

rasagiline O
acts O
as O
NOT O
for O
what O
entity O
? O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O
MAO-A O
as O

well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS B
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O

doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline O
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1) O
. O
Rasagiline O
does O
not O
modify O
CNS B
monoamine O
tissue O
levels O
or O
monoamine-induced O
behavioural O
syndromes O
at O

doses O
which O
selectively O
inhibit O
MAO-B O
but O
not O
MAO-A O
. O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours O
. O
Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O

this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O

Rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours O
. O
Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O

this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O

TVP1012 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012 O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O

this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O

TVP1012 O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[N-propargyl-1R(+)-aminoindan; O
TVP1012 O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O

this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O

rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O

MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O

rasagiline O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O
of O
reserpine O
syndrome O
. O
Reserpine-induced O
ptosis O
was O
reversed O
by O
rasagiline O
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p. O
, O
which O
inhibit O

MAO-A O
as O
well O
as O
MAO-B O
, O
but O
not O
at O
MAO-B-selective O
doses O
. O
However O
, O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O

MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O

tranylcypromine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
combination O
of O
rasagiline O
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O

MAO-B O
by O
tranylcypromine O
together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O

monoamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O

together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O

monoamine O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA O
or O
L-tryptophan O
(50 O
mg O
x O
kg(-1) O
i.p.) O
, O
or O
rasagiline O
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine O
(10 O
mg O
x O
kg(-1) O
p.o.) O
, O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A O
and O
MAO-B O
by O
tranylcypromine O

together O
with O
the O
monoamine O
precursors O
. O
Following O
oral O
administration O
, O
levels O
of O
noradrenaline O
(NA) O
, O
5-hydroxytryptamine O
(5-HT) O
and O
dopamine O
(DA) O
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline O
up O
to O
2 O
mg O
x O
kg(-1) O
. O
Following O
chronic O
oral O
administration O
(21 O
days O
, O
one O
dose O
daily) O
, O
levels O
of O
NA O
, O
5-HT O
and O
DA O
in O
hippocampus O
and O
striatum O

N-propargyl-1R(+)-aminoindan O
acts O
as O
INHIBITOR O
for O
what O
entity O
? O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; O
modification O
of O
endogenous O
brain O
amines O
, O
reserpine O
reversal O
, O
serotonergic O
and O
dopaminergic O
behaviours.Rasagiline O
[ O
N-propargyl-1R(+)-aminoindan O
TVP1012] O
is O
a O
potent O
irreversible O
monoamine O
oxidase O
(MAO) O
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme O
, O
which O

is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease O
. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline O
on O
CNS O
monoamine O
levels O
, O
modification O
of O
behavioural O
response O
to O
L-tryptophan O
, O
fluoxetine O
and O
L-DOPA O
, O
and O
reversal O

